Page last updated: 2024-12-05

isosorbide dinitrate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isosorbide dinitrate is a nitrate ester that is used as a vasodilator to treat angina pectoris. It is synthesized by the nitration of isosorbide. Isosorbide dinitrate acts primarily by relaxing vascular smooth muscle, leading to vasodilation and a decrease in preload and afterload. It is also used to prevent migraine headaches. Isosorbide dinitrate is studied to understand its effects on blood vessels, heart function, and pain management. It is also being investigated for its potential use in treating other conditions, such as pulmonary hypertension and peripheral artery disease.'

Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6883
CHEMBL ID6622
CHEBI ID6061
SCHEMBL ID8253
MeSH IDM0011788

Synonyms (239)

Synonym
AC-12153
DIVK1C_000436
KBIO1_000436
SPECTRUM_000163
BSPBIO_000927
corovliss
einecs 201-740-9
nsc 80038
isomak r
dilatrate
dinitrate d'isosorbide [inn-french]
sst-101
dinitrato de isosorbida [inn-spanish]
glucitol, 1,4:3,6-dianhydro-, dinitrate, d-
isosorbidi dinitras [inn-latin]
disorlon
dilatrate sr
1,4:3,6-dianhydro-d-glucitol dinitrate
frandol
ccris 1910
sorbide
eurecor
dignionitrat
isosorbide dinitrato [dcit]
laserdil
un2907
sorquat
sorbidi nitras
hsdb 3417
iso-mack
tyb 3215
isoket retard 40
diniket
sdm no. 40
isochron
sorate-5
isosorbidi nitras
cardonit 40
sorbidinitrate
sdm no. 50
astridine
langoran
angidil
sorate-10
isodinit
iso-puren
PRESTWICK_81
NCGC00178830-02
NCGC00178830-01
vasodilat
vascardin
sorbidilat
sorbonit
nosim
1,6-dianhydro-d-glucitol dinitrate
carvanil
tinidil
cardis
nitrosorbon
isostat
vasorbate
xanyl
glucitol,4:3,6-dianhydro-, dinitrate, d-
dilatrate-sr
sorbitrate
ibd 20
corosorbide
cardio 10
harrical
nitrosorbid
sorbislo
dinitrosorbide
sorquad
rifloc retard
sorbangil
1,6-dianhydrosorbitol 2,5-dinitrate
nsc80038
isdn
dianhydrosorbitol 2,5-dinitrate
nitrosorbide
sorbide t.d.
iso-bid
isorbid
sorbide, dinitrate
nsc-80038
resoidan
isordil tembids
coronex
cornilat
isordil
sorbide nitrate
flindix
carvasin
maycor
isoket
lomilan
myorexon
claodical
rigedal
cedocard
isotrate
emoper
d-glucitol,4:3,6-dianhydro-, dinitrate
sorbidnitrate
difutrat
ISD ,
korodil
glucitol, 1,4:3, 6-dianhydro-, dinitrate, d-
1,4:3, 6-dianhydro-d-glucitol dinitrate
1,4:3,6-dianhydrosorbitol 2, 5-dinitrate
d-glucitol, 1,4:3,6-dianhydro-, dinitrate
[(3r,3as,6s,6as)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
PRESTWICK3_000714
AB00513900
C07456
isosorbide dinitrate
87-33-2
dinitroisosorbide
isosorbide 2,5-dinitrate
DB00883
1,4:3,6-dianhydrosorbitol 2,5-dinitrate
d-isosorbide dinitrate
dilatrate-sr (tn)
isordil (tn)
D00516
isosorbide dinitrate (jp17/usp/inn)
PRESTWICK2_000714
SPECTRUM5_001057
NCGC00094703-01
KBIO2_000643
KBIO2_003211
KBIO2_005779
KBIO3_001580
KBIOGR_000429
KBIOSS_000643
SPECTRUM2_001069
SPECTRUM3_000600
PRESTWICK0_000714
PRESTWICK1_000714
SPBIO_001058
NINDS_000436
SPECTRUM4_000025
SPBIO_002848
SPECTRUM1500358
BSPBIO_002080
IDI1_000436
BPBIO1_001021
CHEBI:6061 ,
dinitrate d'isosorbide
dinitrate, isosorbide
isosorbidi dinitras
cedocard retard
isoket retard 120
dinitrato de isosorbida
1,4:3,6-dianhydro-2,5-di-o-nitro-d-glucitol
smr000857256
MLS001333562
MLS001333561
HMS2091P05
[(3s,3as,6r,6as)-3-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-6-yl] nitrate
c01da08
diluted-isosorbide dinitrate
diluted isosorbide dinitrate
CHEMBL6622
isomannide-dinitrate
isosorbide dinitrate, diluted
diluted isosorbide dinitrate rs
isosorbidi dinitras dilutes
isosorbidi dinitras dilutus
isosorbide dinitrate, diluted-
HMS501F18
HMS1570O09
HMS1920H15
HMS2097O09
nsc757080
pharmakon1600-01500358
nsc-757080
tox21_111317
dtxsid0045832 ,
dtxcid8025832
HMS2230C09
AKOS015960761
AKOS015994784
CCG-40110
ec 201-740-9
ia7306519n ,
unii-ia7306519n
isosorbide dinitrate [usan:usp:inn:ban:jan]
isosorbide dinitrato
isosorbide dinitrate [who-dd]
isosorbide dinitrate [vandf]
isosorbide dinitrate [hsdb]
isosorbide dinitrate [usp impurity]
isosorbide dinitrate [orange book]
isosorbide dinitrate [inn]
isosorbidi dinitras dilutus [who-ip latin]
diluted-isosorbide dinitrate [who-ip]
bidil component isosorbide dinitrate
isosorbide dinitrate [mart.]
isosorbide dinitrate [usan]
isosorbide mononitrate, diluted impurity b [ep impurity]
isosorbide dinitrate [jan]
isosorbide dinitrate component of bidil
isosorbide dinitrate [mi]
AKOS015895227
[(3s,3as,6r,6as)-6-nitrooxy-2,3,3a,5,6,6a-hexahydrofuro[2,3-d]furan-3-yl] nitrate
gtpl7051
SCHEMBL8253
tox21_111317_1
NCGC00178830-05
W-104033
AB00052026_07
(3r,3as,6s,6as)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate
(3s,3as,6r,6as)-6-(nitrooxy)-hexahydrofuro[3,2-b]furan-3-yl nitrate
GS-6631
sr-05000001658
SR-05000001658-5
mfcd00868238
SR-05000001658-1
SR-05000001658-3
SBI-0051421.P003
HMS3714O09
(3r,3as,6s,6as)-hexahydrofuro[3,2-b]furan-3,6-diyl dinitrate
HY-B1409
CS-0013129
isosorbide dinitrate,(s)
54650-95-2
Q179748
isosorbide-dinitrate
H10018
EN300-222758
Z2044782386
isordiltitradose
isosorbidi dinitras (inn-latin)
dinitrato de isosorbida (inn-spanish)
isosorbide dinitrate (mart.)
isosorbide dinitrate (usan:usp:inn:ban:jan)
isosorbide dinitrate (usp impurity)
dinitrate d'isosorbide (inn-french)

Research Excerpts

Overview

Isosorbide dinitrate is a vasodilator with effects on both arteries and veins and induces opening of vascular layers. It is an effective treatment for anal fissure and is significantly better than placebo.

ExcerptReferenceRelevance
"Isosorbide dinitrate is a vasodilator with effects on both arteries and veins and induces opening of vascular layers."( Isosorbide dinitrate spray as therapeutic strategy for treatment of chronic venous ulcers.
Briseño-Rodríguez, G; Cardona-Muñoz, EG; Gálvez-Gastélum, FJ; Garcia-Benavides, L; Sánchez-Vázquez, R; Totsuka-Sutto, SE,
)
2.3
"Isosorbide dinitrate is an effective portal hypotensive drug."( Vascular hyporeactivity persists despite increased contractility after long-term administration of isosorbide dinitrate in portal hypertensive rats.
Hong, CY; Hou, MC; Huang, YT; Lee, SD; Lin, HC; Tsai, JF, 1998
)
1.24
"Isosorbide dinitrate aerosol (ISA) is a nitric oxide fast-acting donor."( Comparison between isosorbide dinitrate aerosol and nifedipine in the treatment of hypertensive emergencies.
Lozano-Nuevo, JJ; Narvaez-Rivera, JL; Rodriguez-Lopez, L; Rubio-Guerra, AF; Vargas-Ayala, G, 1999
)
1.35
"Isosorbide dinitrate in spray form is an effective and safe option for the treatment of hypertensive emergencies. "( Comparison between isosorbide dinitrate in aerosol and in tablet form for the treatment of hypertensive emergencies in the elderly.
Lozano-Nuevo, JJ; Narváez-Rivera, JL; Ramos-Brizuela, LM; Rodríguez-López, L; Rubio-Guerra, AF; Vargas-Ayala, G, 2000
)
2.08
"Isosorbide dinitrate is an effective treatment for anal fissure, and is significantly better than placebo."( Isosorbide dinitrate in the treatment of anal fissure: a randomised, prospective, double blind, placebo-controlled trial.
Bilgen, EJ; Eggink, WF; Palamba, HW; Werre, AJ, 2001
)
3.2
"Isosorbide dinitrate is an effective vasodilator that improves resting left ventricular performance in patients with congestive heart failure, but little is known of the effect of the drug on the response to exercise. "( Effect of isosorbide dinitrate on response to submaximal and maximal exercise in patients with congestive heart failure.
Cohn, JN; Franciosa, JA, 1979
)
2.1

Effects

Isosorbide dinitrate (ISDN) has an inhibitory effect on platelet aggregation through the generation of nitric oxide (NO)

Isosorbide dinitrate (ISDN) has been used in the treatment of ischaemic cardiovascular diseases for many years. It has a cytoprotective activity on the gastric mucosa of rats submitted to ketoprofen action.

ExcerptReferenceRelevance
"Isosorbide dinitrate has a cytoprotective activity on the gastric mucosa of rats submitted to ketoprofen action."( The cytoprotective effect of a nitric oxide donor drug on gastric mucous membrane of rats treated with ketoprofen, a non-steroidal anti-inflammatory drug.
Campos, AD; Evora, PR; Ramalho, F; Reginaldo, C; Viaro, F; Villa, AL,
)
1.57
"Isosorbide dinitrate (ISDN) has an inhibitory effect on platelet aggregation through the generation of nitric oxide (NO). "( [Inhibitory effect of isosorbide dinitrate on whole blood aggregation].
Higasa, S; Kakishita, E; Oku, KI; Seto, T; Suehiro, A; Yoshimoto, H, 1997
)
2.05
"Isosorbide dinitrate (ISDN) has been used in the treatment of ischaemic cardiovascular diseases for many years. "( The effects of isosorbide dinitrate on methemoglobin reductase enzyme activity and antioxidant states.
Egüz, AM; Inal, ME,
)
1.93
"Isosorbide dinitrate has a cytoprotective activity on the gastric mucosa of rats submitted to ketoprofen action."( The cytoprotective effect of a nitric oxide donor drug on gastric mucous membrane of rats treated with ketoprofen, a non-steroidal anti-inflammatory drug.
Campos, AD; Evora, PR; Ramalho, F; Reginaldo, C; Viaro, F; Villa, AL,
)
1.57
"Isosorbide dinitrate (ISDN) has an inhibitory effect on platelet aggregation through the generation of nitric oxide (NO). "( [Inhibitory effect of isosorbide dinitrate on whole blood aggregation].
Higasa, S; Kakishita, E; Oku, KI; Seto, T; Suehiro, A; Yoshimoto, H, 1997
)
2.05
"Isosorbide dinitrate has thus a more complete and longer lasting protective haemodynamic effect than nitroglycerine."( [Long-term action of nitrites in coronary heart disease (author's transl)].
Beck, OA; Hochrein, H; Krämer, KD; Wolf, R, 1975
)
0.98
"Oral isosorbide dinitrate has been widely used to lower elevated left ventricular filling pressure in patients with chronic heart failure. "( Resistance to isosorbide dinitrate in patients with severe chronic heart failure: incidence and attempt at hemodynamic prediction.
Elkayam, U; Kulick, D; McIntosh, N; Rahimtoola, SH; Roth, A, 1988
)
1.15

Actions

Isosorbide dinitrate may inhibit contraction primarily by enhancing intracellular calcium sequestration, but possibly also by inhibiting agonist-stimulated calcium influx.

ExcerptReferenceRelevance
"Isosorbide dinitrate would produce a shift from A to D in a patient not on digitalis and from C to D in a patient already receiving digitalis."( Treatment of congestive heart failure.
Mantle, JA; Moraski, RE; Rackley, CE; Rogers, WJ; Russel, RO, 1976
)
0.98
"Isosorbide dinitrate may inhibit contraction primarily by enhancing intracellular calcium sequestration, but possibly also by inhibiting agonist-stimulated calcium influx at high isosorbide dinitrate concentrations."( Effects of isosorbide dinitrate and diltiazem on Ca2+ flux and contraction in artery.
Baik, YH; Dubé, GP; Schwartz, A; Van Breemen, C, 1988
)
1.39

Treatment

Isosorbide dinitrate treatment provided 64.6 and 67.6% protection for motor and sensory nerves, respectively (P < 0.01) When treatment was stopped there was a significant increase in the total number and duration of painless episodes of myocardial ischaemia.

ExcerptReferenceRelevance
"Isosorbide dinitrate treatment provided 64.6 and 67.6% protection for motor and sensory nerves, respectively (P < 0.01)."( Effects of chronic treatment with a nitric oxide donor on nerve conduction abnormalities and endoneurial blood flow in streptozotocin-diabetic rats.
Cameron, NE; Cotter, MA, 1995
)
1.01
"Isosorbide dinitrate treatment markedly improved exercise-induced left heart dysfunction, whereas excessive ventilatory response was unaffected, even after 3 h. "( Effects of isosorbide dinitrate on electrocardiography, hemodynamics, and ventilation in patients with exercise-induced elevation of pulmonary artery wedge pressure.
Jørgensen, LH; Refsum, HE; Thaulow, E, 1999
)
2.14
"When treatment with isosorbide dinitrate was stopped there was a significant increase in the total number and duration of painless episodes of myocardial ischaemia. "( Abrupt cessation of short-term continuous treatment with isosorbide dinitrate may cause a rebound increase in silent myocardial ischaemia in patients with stable angina pectoris.
Koutishenko, N; Martsevich, SY; Metelitsa, VI, 1996
)
0.86

Toxicity

The aim of this study was the comparative evaluation of antianginal efficacy and the adverse effects of 3 nitrates in oral doses. The most frequent side effect associated with isosorbide dinitrate administration was headache.

ExcerptReferenceRelevance
" Transient headache was the most prevalent adverse experience."( Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
Bittar, N; Casareto, R; Chrysant, SG; Danisa, K; Ferraresi, R; Garutti, RJ; Glasser, SP; Ibrahim, R; Shahidi, FE; Watts, LE, 1993
)
0.29
" Together with the results of the N(G)-monomethyl-L-arginine and N(G)-nitro-L-arginine experiments, the data suggest that NO plays little or no role in the toxic mechanism of action of METH or MDMA."( Nitric oxide and the neurotoxic effects of methamphetamine and 3,4-methylenedioxymethamphetamine.
Finnegan, KT; Taraska, T, 1997
)
0.3
"Isoket spray is effective and safe antianginal drug."( [Comparative efficacy, safety, cardio-hemodynamic effects of isosorbide dinitrate (ID) aerosol and sublingual tablets of nitroglycerin].
Ol'binskaia, LI; Sizova, ZhM; Ushakova, AV, 1998
)
0.54
"Hartone is a safe and effective anti-anginal agent comparable to ISMN and is better tolerated."( Safety and efficacy of Hartone in stable angina pectoris--an open comparative trial.
Adhikari, P; Bhat, P; Kumar, PU; Pereira, P, 1999
)
0.3
"Patients treated by BiPAP had significantly more adverse events."( High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema.
Blatt, A; Cotter, G; Faigenberg, Z; Golik, A; Kaluski, E; Krakover, R; Metzger, M; Milovanov, O; Moshkovitz, Y; Polak, R; Shaham, O; Sharon, A; Shpirer, I; Simovitz, A; Stav, D; Vered, Z; Yogev, R, 2000
)
0.31
"The aim of this study was the comparative evaluation of antianginal efficacy and the adverse effects of 3 nitrates in oral doses: isosorbide dinitrate 80 mg in slow release form (ISDN-80), nitroglycerin 15 mg--slow release (NITRO-15) and pentaerythritol tetranitrate 100 mg in normal tablets (PENTA-100) in patients (pts) with stable angina pectoris."( [Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
Jedrzejczyk, B; Kośmicki, M; Kowalik, I; Sadowski, Z, 2002
)
0.52
" The headaches, the most frequent adverse effects, occurred after ingestion of ISDN-80 in 6 pts, NITRO-15 in 4 pts, PENTA-100 in 3 pts and P in 1 pt."( [Comparative evaluation of the clinical effectiveness and the adverse effects of three different forms of nitrates in high oral doses in patients with stable angina pectoris].
Jedrzejczyk, B; Kośmicki, M; Kowalik, I; Sadowski, Z, 2002
)
0.31
" Adverse events, such as headache, abdominal pain, pelvic pain, backache, nausea and vomiting, were evaluated."( Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of conce
Arteaga-Troncoso, G; Belmont-Gomez, A; Guerra-Infante, F; Martinez-Herrera, FJ; Villagrana-Zesati, R; Villegas-Alvarado, A, 2005
)
0.58
" Differences in the incidence of non-serious adverse events are not likely to be clinically significant."( Intracervical application of the nitric oxide donor isosorbide dinitrate for induction of cervical ripening: a randomised controlled trial to determine clinical efficacy and safety prior to first trimester surgical evacuation of retained products of conce
Arteaga-Troncoso, G; Belmont-Gomez, A; Guerra-Infante, F; Martinez-Herrera, FJ; Villagrana-Zesati, R; Villegas-Alvarado, A, 2005
)
0.58
" Headache is the most common side effect of nitrates; often dose-related and reported by up to 82% of patients in placebo-controlled trials."( Side effects of using nitrates to treat angina.
Rodgers, T; Thadani, U, 2006
)
0.33
" Although headache was the most frequent adverse effect in the CR-ISMN group, all symptoms were mild and at self-limiting levels."( Efficacy and safety of controlled-release isosorbide-5-mononitrate in Japanese patients with stable effort angina pectoris.
Daida, H; Kawakubo, K; Kusama, Y; Nakazato, K; Satoh, H; Shimada, K; Sunayama, S, 2006
)
0.33
" The most common adverse events, headache (34%) and dizziness (16%), were less than in patients taking ID/H in A-HeFT, with only 6% discontinuations for adverse events."( Evidence for the continued safety and tolerability of fixed-dose isosorbide dinitrate/hydralazine in patients with chronic heart failure (the extension to African-American Heart Failure Trial).
Archambault, WT; Braman, VM; Franciosa, JA; Ghali, JK; Sabolinski, ML; Worcel, M; Yancy, CW, 2007
)
0.58
"Sublingual ISDN is less sensitive and less safe compared to intravenous ISOP in assessing pediatric age patients with suspected neurocardiogenic syncope and with a negative result in tilt test without provocation."( Head-up tilt table testing in syncope: safety and efficiency of isosorbide versus isoproterenol in pediatric population.
Caspi, A; Epstein, M; Paz, O; Shimoni, S; Swissa, M, 2008
)
0.35
" Uterine hyperstimulation with fetal heart rate deceleration and other maternal or fetal adverse events are rare but unpredictable."( Outpatient induction -- how safe.
Rath, WH, 2009
)
0.35
"'Healer' is a promising effective and safe line of treatment in acute and chronic anal fissure."( Study of efficacy and safety of a new local cream ('healer') in the treatment of chronic anal fissure: a prospective, randomized, single-blind, comparative study.
Abdel Salaam, M; Yakoot, M,
)
0.13
" Cardiotoxicity causing angina, arrhythmia and infarction are serious adverse events associated with these agents."( [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Baeksgaard, L; Jensen, SA; Petersen, LN; Reiter, L; Sørensen, JB, 2010
)
0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
" Safety and adverse events were assessed by reported signs and symptoms, physical examinations, blood tests, cardiac and respiratory function tests."( Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients.
Bonato, S; Bresolin, N; Brighina, E; Brunelli, S; Cattaneo, D; Clementi, E; Comi, GP; D'Angelo, MG; Gandossini, S; Magri, F; Martinelli Boneschi, F; Sciorati, C; Stefanoni, G; Turconi, AC, 2012
)
0.38
"After enrolling 11 patients, the study had to be discontinued due to adverse effects."( Interruption of a study of cervical ripening with isosorbide mononitrate due to adverse effects.
Araujo Júnior, E; Auxiliadora de Aquino, MM; de Silva Bussamra, LC; de Souza, E; Hatanaka, AR; Mattar, R; Moron, AF, 2012
)
0.38

Pharmacokinetics

To make a physiologically-based pharmacokinetic model of isosorbide dinitrate (ISDN), the author infused ISDN at 1, 10, 30 micrograms. In a randomized, open-label, three-way crossover trial in 24 healthy men, ISDN was given 40 mg every 6 hours.

ExcerptReferenceRelevance
" These results regarding the pharmacokinetic parameters of BM 12."( Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys.
Bartsch, W; Neidlein, R; Pressmar, F; Strein, K, 1992
)
0.28
"A new galenic form of isosorbide dinitrate (consisting of a hydrophilic matrix which allows very slow release of the active drug) was studied from the pharmacokinetic and pharmacodynamic view points in 11 patients with stable angina pectoris under betablocker therapy."( [Pharmacokinetics and pharmacodynamics of a new 80 mg oral delayed-action isosorbide dinitrate preparation].
Auclert, L; Georges, M; Joly, H; Mialet, C; Olive, G; Pello, JY; Puechavy, C; Rey, E; Ruffo, M, 1992
)
0.83
" Pharmacokinetic modeling of the in vivo time-dependent hemodynamic effects further indicated that the blood compartment data were more consistent with a mechanism of mononitrate action that involves metabolic activation to form nitric oxide and cyclic GMP, rather than direct receptor activation."( Pharmacokinetic/pharmacodynamic relationship of the duration of vasodilating action of organic mononitrates in rats.
Fung, HL; Tzeng, TB, 1992
)
0.28
" The 95% confidence intervals for Cmax and tmax were within the prescribed limits of 70-130%."( [Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms].
Harder, S; Merz, PG; Thürmann, P, 1992
)
0.28
"The possibility of a pharmacokinetic interaction between isosorbide-5-mononitrate (5-ISMN) and epinine, the active metabolite of ibopamine, has been investigated in 8 healthy male subjects given single doses of 200 mg ibopamine and 20 mg 5-ISMN, separately and together."( Investigation of a possible pharmacokinetic interaction between ibopamine and isosorbide-5-mononitrate.
De Sutter, J; De Wilde, G; Duprez, D; Lefebvre, RA; Pocchiari, F; Rosseel, MT, 1992
)
0.28
"The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of two commercial 20-mg isosorbide-5-mononitrate (IS-5-MN) preparations (test and reference preparation) after single oral administration."( Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
Bonn, R; Fritschi, E; Hutt, V; Jaeger, H; Pabst, G; Theodor, R, 1992
)
0.28
" For both formulations, the mean plasma half-life was found to be approximately 5 h after a single dose."( A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Bron, J; De Jong, AP; Jonkman, JH; Oosterhuis, B; Storm, G; Wittebrood, AJ, 1991
)
0.28
"A pharmacokinetic model is proposed to describe the plasma levels of isosorbidedinitrate (ISDN) and its two pharmacologically active metabolites, isosorbide-2-mononitrate (IS-2MN) and isosorbide-5-mononitrate (IS-5MN), following the oral administration of several 20-mg sustained release formulations of ISDN."( A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Aldrich, W; Dey, M; Enever, R; Smith, D; Warner, R; Weierstall, R,
)
0.13
" Noninvasive measurements of peripheral blood flow can serve as a convenient and accurate tool for pharmacokinetic studies of vasoactive drugs."( Pharmacokinetic activity of nitrites evaluated by digital pulse volume recording.
Bass, A; Hirshberg, A; Schneiderman, J; Walden, R,
)
0.13
" Their terminal elimination half-life is 63, 108 and 264 min respectively."( Pharmacokinetics of isosorbide dinitrate and isosorbide-5-mononitrate.
Schaumann, W, 1989
)
0.6
" We found a wide variation of pharmacokinetic parameters (AUCss0-8 and t1/2) of ISDN, IS-2-N, and IS-5-N in our patients."( Pharmacokinetics of isosorbide dinitrate, isosorbide-2-nitrate and isosorbide-5-nitrate in renal insufficiency after repeated oral dosage.
Boertz, A; Bonn, R; Cawello, W; Dickmans, HA; Evers, J; Weiss, M, 1989
)
0.6
"The pharmacokinetic profile and the bioavailability of a new galenic formulation of isosorbide-5-mononitrate sustained released capsules (Olicard 40 retard) was tested under standardized conditions."( [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Böttcher, B; Brandt, L; Skutta, T, 1989
)
0.28
" The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets."( [Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study].
Blagodatskikh, SV; Martsevich, SIu; Metelitsa, VI; Piotrovskiĭ, VK; Riabokon', OS, 1986
)
0.27
"The pharmacokinetic and pharmacodynamic aspects of organic nitrates are discussed, with particular emphasis on the 3 major organic nitrates currently in use, nitroglycerin (NTG), isosorbide dinitrate and isosorbide-5-mononitrate."( Pharmacokinetics and pharmacodynamics of organic nitrates.
Fung, HL, 1987
)
0.47
" On the other hand, perfect dose-linearity of all relevant pharmacokinetic parameters of all three measured isosorbide nitrates was observed for the 20 mg and the 40 mg dose of the capsule."( Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen, H; Leitold, M; Wildfeuer, A, 1988
)
0.49
"Isosorbide 5-mononitrate differs from other clinically used organic nitrate vasodilators because of its almost complete oral absorption, the low intersubject variability in its plasma concentrations and pharmacokinetic parameters, its relatively long half-life and its lack of active metabolites."( Isosorbide 5-mononitrate pharmacokinetics.
Chasseaud, LF, 1987
)
0.27
" There was no relation between the area under the plasma isosorbide dinitrate concentration curve and hemodynamic changes."( Hemodynamic evaluation of isosorbide dinitrate in alcoholic cirrhosis. Pharmacokinetic-hemodynamic interactions.
Blei, AT; Fung, HL; Ganger, D; Garcia-Tsao, G; Groszmann, RJ; Kahrilas, P; Morse, S, 1987
)
0.82
" Pharmacokinetic data showed that the sustained release formulation reached significantly lower and delayed mean peak plasma levels compared with the conventional formulation, respectively 452."( Pharmacokinetics of isosorbide mononitrate in a new sustained release oral form in comparison with a conventional formulation.
Assereto, R; Baggio, E; Castoldi, D; Cunietti, E; Gandini, R; Tofanetti, O, 1987
)
0.27
"The physical characteristics of krypton-81m makes it particularly suited for the study of right ventricular function, but its ultrashort half-life (13."( Measurement of right ventricular volumes from ECG-gated steady-state krypton-81m angiocardiography.
Delcourt, E; Dobbeleir, A; Franken, PR; Georges, B; Ham, HR; Mols, P, 1987
)
0.27
" After intravenous administration until plateau concentrations were reached, the ISDN infusion was stopped in order to study the disappearance curve of the drug and the pharmacokinetic parameters."( Isosorbide dinitrate: relationship between pharmacokinetics and brachial artery hemodynamics in essential hypertension.
Frydman, AM; Gaillot, J; Levenson, JA; Roland, E; Safar, ME; Simon, AC, 1986
)
1.71
"The aim of the study was to determine the relative bioavailability and the pharmacokinetic parameters following administration of a slow-release formulation of isosorbide dinitrate (ISDN, Isdin) capsules (20, 40 and 60 mg)."( [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Gielsdorf, W; Jaeger, H; Loew, D; Lutz, VD; Rasper, J, 1985
)
0.7
" Pharmacokinetic calculations based on plasma concentrations should be viewed with caution, as the data on which these calculations are based are often very limited, and the very rapid disappearance of for example glyceryl trinitrate from plasma makes the choice of an appropriate kinetic model and exact calculations difficult."( Clinical pharmacokinetics of organic nitrates.
Bogaert, MG,
)
0.13
" These results provide an interesting example of divergent pharmacokinetic interactions exhibited by two isomeric metabolites."( Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Fung, HL; Morrison, RA, 1984
)
1.71
" A two-compartment open model was taken as a basis for the calculations of the plasma concentration curves and the pharmacokinetic parameters."( Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel, AT; Steudel, HC; Volkenandt, M, 1983
)
0.27
"The effect of isosorbide 2-mononitrate (IS-2-MN) was compared with that of isosorbide dinitrate (ISDN) in rats regarding the antianginal, haemodynamic and pharmacokinetic properties."( [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
Laufen, H; Leitold, M, 1983
)
0.71
"The aim of this study was to determine pharmacokinetic data of isosorbide-5-mononitrate (IS-5-MN) in dogs and to correlate them with the hemodynamic effects of this drug."( Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
Bartsch, W; Dietmann, K; Endele, R; Kühnle, HF; Sponer, G; Strein, K, 1984
)
0.27
"The present comparative pharmacokinetic study performed to establish the relative bioavailability for an isosorbide dinitrate (ISDN) retard preparation (Sorbidilat-retard) included 6 healthy, male and female volunteers."( [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Degen, J; Geigenberger, A; Maier-Lenz, H, 1982
)
0.73
" The volume of distribution during steady state (Vd beta = 318 +/- 117 I) and the elimination half-life (t1/2 beta = 64."( [Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].
Bertharion, J; Bieder, A; Frydman, A; Gaillot, J; Levenson, J; Safar, M; Simon, A, 1982
)
0.58
" Distribution half-life was extremely rapid (2-5 min)."( Pharmacokinetics of intravenous isosorbide-dinitrate.
Galeazzi, RL; Platzer, R; Reutemann, G, 1982
)
0.26
" The data analysis using a receptor model (plasma concentration-effect curves) yielded sigmoid curves yielded sigmoid curves for 2-MN and 5-MN with similar relative potencies in the range of 20-80% of maximum response providing an upper limit for the pharmacodynamic effect due to ISDN, 2-MN or 5-MN in healthy volunteers."( Relationship between the pharmacodynamics and pharmacokinetics of two oral sustained-release formulations of isosorbide dinitrate in normal man.
Gladigau, V; Johnson, KI; Schnelle, K, 1981
)
0.48
" The time course of plasma concentrations could be described by a two-compartment open model, although a one-compartment open model was adequate for obtaining some pharmacokinetic parameters."( Pharmacokinetics of isosorbide dinitrate in rhesus monkey, cynomolgus monkey, and baboon.
Chasseaud, LF; Doyle, E, 1981
)
0.59
" ISDN was rapidly absorbed and metabolized, having an elimination half-life of 29 min."( Effects and pharmacokinetics of isosorbide dinitrate in normal man.
Abshagen, U; Betzien, G; Kaufmann, B; Liede, V; Spörl-Radun, S, 1980
)
0.54
" The half-life of elimination of isosorbide dinitrate after termination of the infusion was 9--10 min."( Pharmacokinetics of isosorbide dinitrate after intravenous infusion in human subjects.
Chasseaud, LF; Darragh, A; Doyle, E; Fitzgerald, D; O'Kelly, DA; Taylor, T,
)
0.74
"The steady-state pharmacokinetic profile of isosorbide-5-mononitrate (5-ISMN) after oral administration of an extended-release tablet formulation of 5-ISMN 60 mg or 120 mg once a day was compared with that after administration of isosorbide dinitrate (ISDN) 40 mg every 6 hours, in a randomized, open-label, three-way crossover trial in 24 healthy men."( Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
Affrime, MB; Christopher, D; Cohen, A; Kosoglou, T; Patrick, JE; Radwanski, E,
)
0.31
" Isosorbide 5-mononitrate has been studied in its own right as an antianginal agent: it is completely absorbed after oral administration; it has a half-life of around 4 hours, and oral standard and controlled-release formulations have been extensively studied."( Clinical pharmacokinetics of nitrates.
Bogaert, MG, 1994
)
0.29
"In a double-blind, cross-over study the acute clinical efficacy and pharmacokinetic profile of a newly developed isosorbide dinitrate extended-release (ISDN-ER) formulation (10 mg immediate release and 60 mg slow release) were examined in eight angina patients."( A new isosorbide dinitrate extended-release formulation: pharmacokinetic and clinical parameters in patients with stable angina pectoris.
Gjesdal, K; Klemsdal, TO; Mundal, HH; Rudberg, N, 1994
)
0.98
" After the sublingual spray Cmax was higher (39."( Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
Bonn, R; Jähnchen, E; Trenk, D; Vogt, D, 1994
)
0.29
" Pharmacokinetic parameters of the drug was obtained from the human serum level-time curve measured."( [Gas chromatographic method with EC detection to determine isosorbide-5-mononitrate (IS-5-MN) in human serum and its pharmacokinetic parameters].
Dong, SN; Fu, YK; Li, R; Xia, GZ, 1994
)
0.29
"To make a pharmacokinetic model of isosorbide dinitrate (ISDN), we infused ISDN at 1, 10 or 30 micrograms."( [Pharmacokinetics of isosorbide dinitrate studied by the extrapolation model].
Enzan, K; Koizumi, A; Matsumoto, J; Ohtaka, K; Suzuki, M, 1994
)
0.88
"To make a physiologically-based pharmacokinetic model of isosorbide dinitrate (ISDN), the author infused ISDN at 1, 10, 30 micrograms."( [Pharmacokinetics of isosorbide dinitrate examined by physiologically-based pharmacokinetic model].
Matsumoto, J, 1997
)
0.86
" There were no significant differences in the pharmacokinetic parameters for IS-5-MN between the LCFD and the HCFD."( Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
Inoue, K; Kuroda, T; Nii, T; Sata, H, 1997
)
0.51
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
" Pharmacokinetic data showed that with the test tablet significantly lower and delayed mean peak plasma levels (Cmax) were reached compared with the reference preparation in both single and multiple dose studies."( Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
Fu, L; Huang, X; Ji, P; Wei, S; Yan, B; Zhang, Q, 1998
)
0.3
" The major pharmacokinetic parameters of domestic and imported 5-IM sustained-release capsule with a 5-d multiple dose were respectively: Cmax (677 +/- 103) and (702 +/- 76) micrograms."( Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Ding, Y; Huang, DK; Jiang, ZH; Luo, JP; Luo, WX; Peng, JH; Qiu, J; Shen, JP; Sheng, LS; Zhang, YD, 1999
)
0.3
" The pharmacokinetic characteristics of 5-ISMN in ten human volunteers after a single oral dose of 20 mg 5-ISMN were investigated."( [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
Yang, LL; Yuan, YS; Zhao, FL, 1997
)
0.3
"The pharmacokinetic parameters of two oral formulations of 20 mg tablets of isosorbide-5-mononitrate (CAS 16051-77-7, Dilavenil as test and another commercially available preparation as reference) were compared in an open-label, randomized, single oral dose, two-period cross-over design in 20 healthy volunteers under fasting conditions."( Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers.
Daftsios, AC; Nikolaidis, N; Niopas, I, 2002
)
0.31
" Pharmacokinetic data showed that the sustained release formulation reached mean peak plasma levels significantly later and lower minimum plasma concentration (Cmin), compared with the conventional preparation."( [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Fu, L; Huang, X; Ji, P; Wei, S; Yan, B; Zhang, Q, 1998
)
0.3
" On the other hand isosorbide dinitrate significantly increased digoxin maximum serum concentration but without change in the other digoxin pharmacokinetic parameters."( A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure.
Abdulatif, AS; El-Medany, AH; Mahgoub, AA, 2002
)
0.9
" Various pharmacokinetic parameters including AUC0-t, AUC0-infinity, Cmax, tmax, t1/2, Kelm and MRT were determined for the three formulations and found to be in good agreement with literature values."( Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Cai, L; Chen, J; Gao, KP; Jiang, XG; Lu, W; Shi, ZQ; Zhang, QZ, 2004
)
0.32
"The difference found in the Cmax and AUC(SS)/kg of isosorbide-5-mononitrate between male and female subjects must be due to the difference in dose/kg, following a standard dose of 60 mg."( Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
Dammers, E; Valducci, R; Vree, TB, 2004
)
0.32
"Human pharmacokinetic parameters are often predicted prior to clinical study from in vivo preclinical pharmacokinetic data."( Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Jolivette, LJ; Ward, KW, 2005
)
0.33
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Pharmacokinetic assessments were taken at regular intervals over 24 h after dosing on the last day of each treatment period."( Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Antunes, A; Bartlett, M; Dieterich, HA; Dole, WP; Howard, D; Vaidyanathan, S; Yeh, CM, 2008
)
0.35
" And then this method was successfully applied to a pharmacokinetic investigation on isosorbide dinitrate oral spray in healthy volunteers."( A simple and sensitive gas chromatography method for determination of isosorbide dinitrate and its metabolites in human plasma: application to pharmacokinetics study on oral spray.
Guo, J; Guo, R; Jiang, Z; Li, R; Sun, Z; Wei, C; Yuan, G; Zhang, R, 2014
)
0.86
"This study was performed to compare the pharmacokinetic properties and relative bioavailability of two isosorbide-5-mononitrate (5-ISMN) sustained-release drugs in healthy Korean subjects under fasting and fed conditions."( Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
Bentz, J; Chae, SW; Im, YJ; Jeon, JY; Jeong, JA; Jin, C; Kim, MG; Kim, Y; Kumke, T, 2015
)
0.42
" The pharmacokinetic parameters were calculated, and the 90% confidence intervals (CIs) of the geometric mean ratio (test/reference) of the parameters were obtained by analysis of variance on logarithmically transformed data."( Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
Bentz, J; Chae, SW; Im, YJ; Jeon, JY; Jeong, JA; Jin, C; Kim, MG; Kim, Y; Kumke, T, 2015
)
0.42
"The corresponding 90% CIs of AUClast and Cmax for the test/reference geometric mean ratio were 90."( Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
Bentz, J; Chae, SW; Im, YJ; Jeon, JY; Jeong, JA; Jin, C; Kim, MG; Kim, Y; Kumke, T, 2015
)
0.42

Compound-Compound Interactions

In 18 patients (17 male and 1 female, 40 to 63 years old) with coronary heart disease, a randomized double-blind study was carried out. The antiischemic effects of 5, 10 and 20 mg isosorbide dinitrate (ISDN) alone and in combination with gallopamil (G: 25 and 50 mg) or 80 mg propranolol (P: 80 mg) were compared to placebo.

ExcerptReferenceRelevance
"The response to verapamil alone and combined with isosorbide dinitrate in a group of 12 patients with severe ischemic heart disease and stable effort angina was assessed by means of serial treadmill testing."( [Evaluation using serial exercise tests of verapamil alone and combined with isosorbide dinitrate in exertional angina].
Colman, T; González-Vílchez, F; Pajarón, A; Ruano, J; Vázquez de Prada, JA; Zueco, J, 1989
)
0.76
"In 18 patients (17 male and 1 female, 40 to 63 years old) with coronary heart disease, a randomized double-blind study was carried out to investigate in comparison to placebo, the antiischemic effects of 5, 10 and 20 mg isosorbide dinitrate (ISDN) alone and in combination with gallopamil (G: 25 and 50 mg) or 80 mg propranolol (P: 80 mg) on the ischemic ST-segment-depression in standardized exercise ECGs."( [The anti-ischemic effect of isosorbide dinitrate alone and in combination with gallopamil and propranolol].
Hopf, R; Kaltenbach, M; Sthler-Klich, HM, 1989
)
0.75
" Using a randomized, double-blind, placebo-controlled protocol, the effects of nadolol alone and nadolol in combination with isosorbide dinitrate and nifedipine were compared, in low and high doses, on antianginal efficacy, respiratory functions and arterial blood oxygen saturation (SaO2) in 19 patients with stable angina pectoris."( Cardiorespiratory effects of isosorbide dinitrate and nifedipine in combination with nadolol: a double-blind comparative study of beneficial and adverse antianginal drug interactions.
Mir, MA; Tirlapur, VG, 1984
)
0.77
" In contrast, mannitol, isosorbide dinitrate, and propranolol, each combined with IABP support, produced significant improvements in collateral flow within the same time periods."( Intraaortic balloon counterpulsation: its influence alone and combined with various pharmacological agents on regional myocardial blood flow during experimental acute coronary occlusion.
Barnett, PA; Dengle, SK; Eberhart, RC; Jett, GK; Platt, MR; Watson, JT; Willerson, JT, 1981
)
0.57
" We investigated the hemodynamic effects of isosorbide dinitrate, alone and in combination with vasopressin, in patients with liver cirrhosis."( Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.
Hallemans, R; Mélot, C; Mols, P; Naeije, R; Reding, P, 1983
)
0.8
"High dose ISDN is safer and better than BiPAP ventilation combined with conventional therapy in patients with severe pulmonary edema."( High-dose intravenous isosorbide-dinitrate is safer and better than Bi-PAP ventilation combined with conventional treatment for severe pulmonary edema.
Blatt, A; Cotter, G; Faigenberg, Z; Golik, A; Kaluski, E; Krakover, R; Metzger, M; Milovanov, O; Moshkovitz, Y; Polak, R; Shaham, O; Sharon, A; Shpirer, I; Simovitz, A; Stav, D; Vered, Z; Yogev, R, 2000
)
0.31
" Large and sudden decreases in systemic blood pressure were reported in a substantial number of patients taking sildenafil citrate combined with nitroglycerin."( Effects of sildenafil citrate (Viagra) combined with nitrate on the heart.
Beppu, S; Hamada, T; Ishikura, F; Khandheria, BK; Nehra, A; Seward, JB, 2000
)
0.31
"To investigate the apoptosis of Hep-A cells induced by hyperthermia combined with Nitric Oxide donor (Isosorbide dinitrate, ISDN) and its mechanism."( [Experimental research on the apoptosis of Hep-A cells induced by hyperthermia combined with ISDN].
Feng, ZZ; Li, JC; Yang, ZR, 2004
)
0.54
"This study was sought to compare the sensitivity, specificity and accuracy of (1) dual isotope simultaneous acquisition single-photon emission computed tomography (DISA SPECT) myocardial image with (99m)Tc-sestamibi/(18)F-fluorodeoxyglucose ((99m)Tc-MIBI/(18)FDG); (2) low dose dobutamine alone and combined with Isosorbide Dinitrate (ISDN: Isoket) stress two dimensional echocardiography (2DE) to predict regional movement recovery after revascularization (CRV) in patients with old myocardial infarction (OMI) and severe left ventricular dysfunction."( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction].
Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005
)
0.5
"9%) underwent low dose dobutamine 10 microg x kg(-1) x min(-1) (Dob10 microg) and ISDN (286 +/- 31 microg/min) combined with Dob5 microg (ISDN-Dob 5 microg) 2DE and DISA SPECT within one week."( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction].
Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005
)
0.33
" When ISDN combined with Dob5 microg, the sensitivity (91."( [Head to head comparison of dobutamine alone and combined with nitrate stress echocardiography and 99mTc-MIBI/18FDG myocardial SPECT image for diagnosis of viable myocardium in patients with severe left ventricular dysfunction].
Chen, JL; Chen, ZJ; Gao, RL; He, ZX; Hu, FH; Shi, RF; Tian, YQ; Wang, YW; Yang, WX; Yang, YJ; Ye, L; You, SJ, 2005
)
0.33
"The aim of this study was to investigate the effect of the nitric oxide donor isosorbide-5-mononitrate (5-ISMN) alone or in combination with the natural hepatoprotectant with anti-oxidant activity silymarin on the carbon tetrachloride (CCl(4))-induced hepatic injury in rats."( Hepatoprotective effects of the nitric oxide donor isosorbide-5-mononitrate alone and in combination with the natural hepatoprotectant, silymarin, on carbon tetrachloride-induced hepatic injury in rats.
Abdel Salam, OM; Shafee, N; Sleem, AA, 2010
)
0.36
" Administered with losartan 100 mg or alone, ISMN lowered AIx, demonstrating that acute effects of a nitrate donor are much larger than those of an ARB even when administered with an ARB."( Single-dose effects of isosorbide mononitrate alone or in combination with losartan on central blood pressure.
Bolognese, JA; Feig, PU; Herman, GA; Kaufman, R; McCarthy, JM; Miller, DL; Nunes, I; Salotti, D; Smith, WB,
)
0.13
"Based on real world research the circumstances of the clinical use of usual drugs combined with salvianolate injection are surveyed."( [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world].
Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013
)
0.39
"In 1 605 patients with coronary heart disease (CHD), salvianolate injection was most frequently (51%) combined with clopidogrel and isosorbide dinitrate."( [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world].
Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013
)
0.59
"In the real world, salvianolate injection combined with usual treatment was found to be more effective than other treatment combinations."( [Analysis of salvianolate injection combined with usual drugs in treatment of coronary heart disease in real world].
Chang, YP; Hu, J; Xie, YM; Zeng, XB; Zhang, H; Zhuang, Y, 2013
)
0.39

Bioavailability

The relative bioavailability of isosorbide dinitrate (ISDN) and its mononitrate metabolites (IS-2-MN, IS-5-MN) was determined under repetitive dose conditions in 8 healthy volunteers using a randomised, crossover design.

ExcerptReferenceRelevance
"The bioavailability of isosorbide dinitrate (ISDN) and the time course of its serum concentration produced by a standard 20-mg tablet and a sustained-release capsule were compared in six normal volunteers."( Serum concentrations of isosorbide dinitrate produced by a sustained-release capsule.
Almog, S; Friedman, E; Halkin, H, 1979
)
0.88
" Because of probable rapid first-pass metabolism, the bioavailability of isosorbide dinitrate after administration of the oral dose of the standard tablet was 58% of that from the sublingual dose, and the bioavailability from the sustained-release tablet was 47% of that from the sublingual dose of the standard tablet."( Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
Assinder, DF; Chasseaud, LF; Taylor, T, 1977
)
0.94
" Bioavailability parameters were better correlated to the dose over the range 20--60 mg than over the range 20--100 mg."( Plasma concentrations of isosorbide dinitrate after administration of increasing doses of a sustained-release formulation to human subjects.
Chasseaud, LF; Darragh, A; Major, RM; O'Kelly, DA; Taylor, T, 1978
)
0.56
" The mean bioavailability of isosorbide dinitrate from the ointment was estimated as 30 per cent of that from the sublingual tablet when corrected for differences in dose/body weight ratio."( Plasma concentrations of isosorbide dinitrate after cutaneous and sublingual doses to human subjects.
Chasseaud, LF; Darragh, A; Doyle, E; Mansel-Jones, D; O'Kelly, DA; Over, H; Taylor, T,
)
0.73
" The total bioavailability of BM 12."( Pharmacokinetics of the organic nitrates trans-2-amino-2-methyl-N-(4- nitroxycyclohexylmethyl)-propionamide in dogs, and of 4-(2-nitroxyethyl)-piperidine in dogs and in monkeys.
Bartsch, W; Neidlein, R; Pressmar, F; Strein, K, 1992
)
0.28
" Comparative bioavailability data of the two forms after single administration in 12 healthy subjects enabled calculation of the steady state blood levels of ISDN, IS-2MN and IS-5MN by simultation of the two regimens."( [Nycthemeral changes in plasma concentrations of active nitrate derivatives. Comparison of a single dose of LP 60mg isosobide dinitrate and LP 20mg isosobide dinitrate administered 3 times daily].
Auclert, L; Dorléac, D; Guillou, J; Olive, G; Ollivier, JP; Pello, JY, 1992
)
0.28
" The lack of pharmacokinetic data is related to the difficulty in assaying nitrates and there are at present no definitive data describing the effect of aging on their bioavailability or elimination."( Nitrates in the elderly. Pharmacological considerations.
Kelly, JG; O'Malley, K,
)
0.13
" The relative bioavailability of ISDN applied buccally, however, was more than twice that after oral application."( [Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].
Keller-Stanislawski, B; Marschner, JP; Rietbrock, N, 1992
)
0.57
"The bioavailability of 3 different commercial available isosorbide mononitrate (IS-5-MN; CAS 16051-77-7) 40 mg slow-release preparations (A, B and reference formulation C) was determined after oral application to 18 healthy volunteers in a randomized cross-over study."( [Biological availability and pharmacodynamics following single oral administration or three different sustained-release isosorbide-5-mononitrate dosage forms].
Harder, S; Merz, PG; Thürmann, P, 1992
)
0.28
"The objective of this study was to determine both the pharmacokinetic parameters and the bioavailability of two commercial 20-mg isosorbide-5-mononitrate (IS-5-MN) preparations (test and reference preparation) after single oral administration."( Evaluation of bioavailability and pharmacokinetics of two isosorbide-5-mononitrate preparations in healthy volunteers.
Bonn, R; Fritschi, E; Hutt, V; Jaeger, H; Pabst, G; Theodor, R, 1992
)
0.28
" ISDN bioavailability was higher after morning than after evening administration and hemodynamic effects were more pronounced in the evening than in the morning."( Chronopharmacology of oral nitrates in healthy subjects.
Lemmer, B; Scheidel, B, 1991
)
0.28
"Assessment of Bioavailability of Organic Nitrates/Comparative bioavailability study of sustained-release isosorbide dinitrate preparations."( [Bioavailability and bioequivalence of organic nitrates. Isosorbide dinitrate--a study of sustained-release preparations].
Babej-Dölle, RM; Blume, H; Scheidel, B; Siewert, M; Stenzhorn, G, 1991
)
0.74
" This model is of particular usefulness as a formulation tool in designing sustained release ISDN formulations of the type investigated here since the observed first-order absorption rate constant correlates well with the in vitro first-order dissolution rate constant."( A pharmacokinetic model for isosorbidedinitrate, isosorbide-2-mononitrate, and isosorbide-5-mononitrate.
Aldrich, W; Dey, M; Enever, R; Smith, D; Warner, R; Weierstall, R,
)
0.13
" Experimental examinations revealed that Nitrogranulong showed the same bioavailability as Nitro-Mack-Retard and sustac, produced a prolonged coronarolytic effect, and caused the hemodynamic and ECG changes typical of trinitroglycerol."( [Pharmacodynamics and results of a clinical trial of nitrogranulong, a new Soviet long-acting preparation of nitroglycerin].
Alibekov, SD; Belova, LF; Belozerova, OP; Ivanov, AA; Rusakova, KA; Sakovich, GS; Sokolov, SIa; Trumpe, TE, 1990
)
0.28
" A significant loss in relative bioavailability was observed for (A) with 82."( [Bioavailability of sustained-release and nonsustained-release isosorbide-5-mononitrate].
Bonn, R; Muck, B; Rietbrock, N, 1989
)
0.28
" In a three-period change-over study, two other commercial SR preparations exhibited only 79% and 53% of the bioavailability of the new formulation, which was significant in both cases."( Performance of a slow-release formulation of isosorbide-5-mononitrate (ISMO retard).
Akpan, W; Jaeger, H; Lutz, D; Mosberg, H; Neugebauer, G; Stemmle, B, 1989
)
0.28
"The pharmacokinetic profile and the bioavailability of a new galenic formulation of isosorbide-5-mononitrate sustained released capsules (Olicard 40 retard) was tested under standardized conditions."( [Pharmacokinetic profile and bioavailability of a new pharmaceutical formulation of isosorbide-5-mononitrate sustained-release formulation].
Böttcher, B; Brandt, L; Skutta, T, 1989
)
0.28
"The bioavailability of isosorbide dinitrate from an oral therapeutic system (OTS) and from tablet Sorbonit Prolongatum 20,0 mg in 6 volunteers employing a crossover method was studied."( Bioavailability of isosorbide dinitrate from an oral therapeutic system and from tablet Sorbonit Prolongatum 20,0 in human volunteers.
Deptulski, T; Janicki, S; Sawicki, W, 1989
)
0.92
" In the rat 3 shows a bioavailability and an acute toxicity inferior to those of 5-ISMN after oral administration."( New isosorbide 5-mononitrate derivative with hypotensive activity.
Borella, F; Comini, A; Coppi, G; Dall' Asta, L; Gatti, MT, 1989
)
0.28
" The results of pharmacokinetic studies show that DNL bioavailability is 491 +/- 240% as compared to conventional oral IDN tablets."( [Dinitrosorbilong--a new Soviet anti-angina preparation. Its comparative pharmacodynamic, pharmacokinetic and clinical study].
Blagodatskikh, SV; Martsevich, SIu; Metelitsa, VI; Piotrovskiĭ, VK; Riabokon', OS, 1986
)
0.27
" We conclude that the metabolism of ISDN and GTN by the GIT may contribute to the high clearance of these organic nitrates, and the low oral bioavailability of ISDN."( Patterns of isosorbide dinitrate and glyceryl trinitrate metabolites formed by selected segments of the rabbit gastrointestinal tract.
Bennett, BM; Brien, JF; MacMillan, H; Marks, GS; Nakatsu, K; Tam, GS, 1988
)
0.65
" In terms of areas under the curve, the mean bioavailability of the 40 mg sustained release capsule relative to the reference formulation was 198% with respect to ISDN, and 197% both with respect to IS-2-N and IS-5-N."( Comparative pharmacokinetics of isosorbide nitrates after repeated doses of sustained release isosorbide dinitrate.
Laufen, H; Leitold, M; Wildfeuer, A, 1988
)
0.49
" Bioavailability of slow-release isosorbide-5-mononitrate is therefore unaffected by food, but there is a slower rate of absorption."( The effect of food on the absorption of slow-release isosorbide-5-mononitrate tablets.
Green, ST; Miller, SH; Thomson, AH; Whiting, B, 1988
)
0.27
" The results indicate that a well-absorbed substance such as isosorbide-5-nitrate is absorbed from the stomach and small intestinal in a manner that is controlled by the properties of the pellets."( Investigation of the gastrointestinal transit and in vivo drug release of isosorbide-5-nitrate pellets.
Boertz, A; Cawello, W; Cordes, G; Davis, SS; Fischer, W; Khosla, R; Sandrock, K, 1987
)
0.27
" The sustained release preparations showed a low loss of bioavailability of 13-19% as compared to the nonretarded standard formulations."( [Bioavailability of delayed-action and non-delayed-action preparations of isosorbide-5-nitrate].
Gracien, E; Heidemann, R; Menke, G; Rietbrock, N, 1987
)
0.27
"Isosorbide 5-mononitrate (IS 5-MN) has favourable pharmacodynamic properties, such as the specific half-life (close to 5 h) and the bioavailability (100% after oral ingestion)."( Oral isosorbide 5-mononitrate can protect from myocardial ischemia induced by ergonovine test and by isometric effort. Preliminary results from an echocardiographic acute study in anginal patients.
Distante, A; L'Abbate, A; Lombardi, M; Morales, MA; Moscarelli, E, 1987
)
0.27
"The relative bioavailability of isosorbide dinitrate (ISDN) and its mononitrate metabolites (IS-2-MN, IS-5-MN) was determined under repetitive dose conditions in 8 healthy volunteers using a randomised, crossover design."( [Bioavailability of isosorbide dinitrate and isosorbide-5-mononitrate under steady-state conditions].
Knoll, J; Menke, G; Merz, PG; Rietbrock, N, 1985
)
0.88
" Significant advances in nitrate formulations and delivery systems have been made in providing better bioavailability and sustained plasma concentrations of these drugs."( Nitrate formulations and drug delivery systems--an overview.
Fung, HL, 1985
)
0.27
" In the past few years, convincing data have been obtained in patients showing that intact ISDN is significantly bioavailable to the systemic circulation after oral administration; the oral bioavailability is about 20% relative to an intravenous dose and about 45% relative to a sublingual dose, with the balance metabolized to isosorbide mononitrates."( Pharmacokinetics and pharmacodynamics of isosorbide dinitrate.
Fung, HL, 1985
)
0.54
"The aim of the study was to determine the relative bioavailability and the pharmacokinetic parameters following administration of a slow-release formulation of isosorbide dinitrate (ISDN, Isdin) capsules (20, 40 and 60 mg)."( [Comparative study of the bioavailability and pharmacokinetics of isosorbide dinitrate formulations in retard form and in standard preparations by determination of isosorbide-5-mononitrate].
Gielsdorf, W; Jaeger, H; Loew, D; Lutz, VD; Rasper, J, 1985
)
0.7
"We studied the kinetics of isosorbide dinitrate (ISDN) after a dose of 5 mg iv and the bioavailability of a sublingual and an oral preparation of ISDN."( Isosorbide dinitrate bioavailability, kinetics, and metabolism.
Galeazzi, RL; Straehl, P, 1985
)
2.01
" The present results suggest that 5-ISMN shows a high bioavailability and a potency comparable to ISDN, especially in the case of peroral administration."( [Effects of isosorbide 5-mononitrate on cardiovascular function. (I). Effects on the left ventricular system].
Kogi, K; Saito, T, 1985
)
0.27
" It has also proved valuable in determining the relative bioavailability of representatives of this class of drugs."( Digital pulse plethysmography--a tool for investigating vasoactive substances.
Neugebauer, G; von Möllendorff, E, 1985
)
0.27
"The relative bioavailability of isosorbide-5-mononitrate from two different formulations (MONOCLAIR, ISMO) was investigated in a double-blind randomized cross-over study in 8 healthy human subjects."( Pharmacokinetics and bioavailability of isosorbide-5-mononitrate in humans.
Bacher, S; Eichler, HG; Horwatitsch, H; Rameis, H, 1985
)
0.27
"An oral dose of 14C-bupranolol hydrochloride was well absorbed by humans (100 mg), dogs (1 mg/kg), and rhesus monkeys (1 mg/kg)."( Metabolic fate of the beta-blocker 14C-bupranolol in humans, dogs, and rhesus monkeys.
Bonn, R; Chasseaud, LF; Darragh, A; Down, WH; Doyle, E; Girkin, R; Taylor, T; Waller, AR,
)
0.13
" After oral administration, plasma concentrations are very low; with sublingual or cutaneous administration, higher plasma concentrations can be obtained, suggesting a high first-pass extraction after oral administration, but quantitative data on bioavailability are lacking."( Clinical pharmacokinetics of organic nitrates.
Bogaert, MG,
)
0.13
" The specific and sensitive HPLC-TEA method developed in this study provides a reliable and rapid assay for the routine analysis for metabolism or bioavailability studies of nitrate esters and their metabolites in plasma of blood, with a detection limit as low as 1 ng ml-1."( Measurement of plasma concentrations of vasodilators and metabolites by the TEA Analyzer.
Goff, EU; Yu, WC,
)
0.13
" At a dose of 2 mg/kg, the oral bioavailability of ISDN was found to be about 40%."( Isosorbide dinitrate disposition in the rat: metabolite pharmacokinetics and interactions.
Fung, HL; Morrison, RA, 1984
)
1.71
" The explanation could be a higher bioavailability and/or a lower systemic clearance, due to shunting and hepatic cell dysfunction."( Fate of orally given isosorbide dinitrate in cirrhotic patients.
Bogaert, MG; Elewaut, A; Rosseel, MT, 1984
)
0.59
"The relative bioavailability of isosorbide-5-mononitrate (IS-5-MN) has been determined after a 3-day period of dosing with 20 mg in standard-release reference tablets and sustained-release capsules at 12-h intervals, 40 mg in sustained-release capsules (Olicard 40 retard) at 24-h intervals and after single oral dose of 60 mg sustained-release capsules (Olicard 60 retard), in a cross-over study with 12 human subjects."( [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
Chasseaud, LF; Cook, SC; Darragh, A; Lambe, RF; Leaf, FC; Major, RM; Taylor, T, 1984
)
0.27
" This suggests that tolerance is unlikely to be caused by reduced bioavailability or accelerated elimination of ISDN."( Tolerance to isosorbide dinitrate: rate of development and reversal.
Fung, HL; Parker, JO; Ruggirello, D; Stone, JA, 1983
)
0.64
" Relative bioavailability of the latter reached 111%."( Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations.
Galeazzi, RL; Platzer, R; Reutemann, G, 1983
)
0.72
" The time-averaged hepatic extraction of ISDN, at about 70%, agreed with its oral bioavailability in patients."( Hepatic extraction of isosorbide dinitrate in cardiac patients.
Fung, HL; Höhmann, D; Jähnchen, E; Kasper, W; Meinertz, T; Morrison, RA; Wiegand, UW, 1983
)
0.58
"Plasma concentrations and bioavailability of isosorbide dinitrate (ISDN) and its active metabolites isosorbide 2-mononitrate (2-ISMN) and isosorbide 5-mononitrate (5-ISMN) from two sustained-release formulations and one standard-release formulation of isosorbide dinitrate were compared."( Bioavailability of isosorbide dinitrate and its two mononitrate metabolites from sustained-release formulations.
Chasseaud, LF; Darragh, A; Doyle, E; Lambe, RF; Taylor, T, 1983
)
0.85
" The bioavailability of isosorbide dinitrate from this sustained-release formulation was about 90% of that from a standard formulation."( Newer aspects of the pharmacokinetics of organic nitrates.
Chasseaud, LF, 1983
)
0.57
"The pharmacokinetics and bioavailability of IS-5-MN after single-dose oral and intravenous application were investigated over 24 h in three patients with liver cirrhosis and compared with normal subjects."( Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: first results.
Steudel, AT; Steudel, HC; Volkenandt, M, 1983
)
0.27
" Food reduced the apparent absorption rate of oral ISDN."( Effects of disease, route of administration, cigarette smoking, food intake on the pharmacokinetics and circulatory effects of isosorbide dinitrate.
Fung, HL; Parker, JO; Ruggirello, D; Stone, JA, 1983
)
0.47
" The bioavailability of IS-2-MN in the rat was 100%."( [Comparative antianginal, hemodynamic and pharmacokinetic effects of isosorbide-2-mononitrate and isosorbide dinitrate in the rat].
Laufen, H; Leitold, M, 1983
)
0.48
"To study the influence of various in vitro release rates and of coadministration with food on bioavailability of isosorbide dinitrate (ISDN; isoket retard 40) and its mononitrate metabolites from sustained-release formulations the pharmacokinetics of two experimental batches of tablets with different release rates containing 40 mg 14C-ISDN each were studied in six human volunteers."( [Pharmacokinetics of 14C-isosorbide dinitrate after administration in various sustained-release formulations].
Chasseaud, LF; Darragh, A; Lambe, RF; Luckow, V; Major, RM; Taylor, IW; Taylor, T, 1983
)
0.78
" From the comparison of the areas under the curve, a bioavailability of 71."( Pharmacokinetic aspects of isosorbide-5-mononitrate in dogs.
Bartsch, W; Dietmann, K; Endele, R; Kühnle, HF; Sponer, G; Strein, K, 1984
)
0.27
"The bioavailability of isosorbide dinitrate from formulations containing 5, 10, and 20 mg in tablets and 10 mg in solution for oral use and 5 mg in tablets for sublingual use, has been compared."( Isosorbide dinitrate plasma concentrations and bioavailability in human subjects after administration of standard oral and sublingual formulations.
Chasseaud, LF; Darragh, A; Doyle, E; Lambe, RF; Taylor, T, 1984
)
2.02
" In six patients, sublingual ISDN (5 mg) was also given and mean bioavailability of 59% (19% to 93%) for this route was determined."( Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
Bechtold, H; Fung, HL; Höhmann, D; Jähnchen, E; Meinertz, T; Morrison, RA; Wiegand, UW, 1983
)
1.71
"The present comparative pharmacokinetic study performed to establish the relative bioavailability for an isosorbide dinitrate (ISDN) retard preparation (Sorbidilat-retard) included 6 healthy, male and female volunteers."( [Comparative pharmacokinetics and bioavailability of isosorbide dinitrate and its metabolites isosorbide 5- and 2-mononitrate from delayed-release preparations].
Degen, J; Geigenberger, A; Maier-Lenz, H, 1982
)
0.73
" Comparison of the results obtained by the intravenous route with previously published results after perlingual and oral administration indicates the following bioavailability ratios: perlingual/i."( [Pharmacokinetics of isosorbide dinitrate administered by intravenous infusion to hypertensive patients (author's transl)].
Bertharion, J; Bieder, A; Frydman, A; Gaillot, J; Levenson, J; Safar, M; Simon, A, 1982
)
0.58
"The plasma concentrations and bioavailability of sustained-release isosorbide dinitrate and standard-release pindolol have been compared after administration of these drugs in combination and alone."( Plasma concentrations and bioavailability of isosorbide dinitrate and pindolol from a combination formulation.
Chasseaud, LF; Darragh, A; Doyle, E; Taylor, T,
)
0.63
" This suggests that the system employed is useful in evaluating the bioavailability of various preparations of organic nitrates (ISDN)."( [Pharmacodynamic effects of the sustained-release tablet of isosorbide dinitrate and its bioavailability in conscious dogs (author's transl)].
Chida, S; Kimura, T; Kogi, K; Saito, T, 1980
)
0.5
"We evaluated the effect of a high-fat breakfast and gastric emptying rate on the oral bioavailability of a isosoribide-5-mononitrate (5-ISMN) controlled-release tablet formulation (IMDUR 60-mg tablets, Astra Hässle AB, Mölndal, Sweden) relative to an oral solution in 18 healthy men."( Effect of food on the oral bioavailability of isosorbide-5-mononitrate administered as an extended-release tablet.
Affrime, MB; Christopher, D; Flannery, BE; Heimark, L; Kazierad, DJ; Kosoglou, T; Patrick, JE; Radwanski, E; Schentag, JJ, 1995
)
0.29
" A good correlation was demonstrated between the absorption rate constant, ka and the dissolution rate constant, kd."( Release of isosorbide dinitrate from polymer film dosage forms and absorption of this drug through the oral mucosa of rats.
Danjo, K; Kitamura, Y; Miyagawa, Y; Otsuka, A, 1994
)
0.68
" Thus, compared to the spray, the relative bioavailability of ISDN was 48% and 28% from the sublingual and peroral tablets, respectively."( Pharmacokinetics and haemodynamic effects of ISDN following different dosage forms and routes of administration.
Bonn, R; Jähnchen, E; Trenk, D; Vogt, D, 1994
)
0.29
" The relative bioavailability with respect to a reference preparation for AUC related to isosorbide dinitrate was 107."( [Study of the bioequivalence of a new isosorbide dinitrate tablet formulation compared with the standard preparation].
Buchberger, D; Häring, N; Läuter, J; Metzner, JE, 1997
)
0.79
"The aim of this study was to investigate the bioavailability of isosorbide mononitrate (IS-5MN) after oral administration of Monocard 20 mg-capsules, made in "Synteza" â Pharmaceutical-Chemical Company in Poznań."( [The evaluation of the bioavailability of isosorbide 5-mononitrate].
Drobnik, L; Dyderski, S; Szkutnik, D; Szymańska-Shawkat, E, 1999
)
0.3
"The bioavailability of IS-5MN after oral administration of Monocard 20 mg is the same as after oral administration of Effox 20 mg, whose clinical efficacy was tested before."( [The evaluation of the bioavailability of isosorbide 5-mononitrate].
Drobnik, L; Dyderski, S; Szkutnik, D; Szymańska-Shawkat, E, 1999
)
0.3
"Simulated pharmacokinetic (PK) studies were done to determine the effect of intrinsic clearance (CL(INT)) on the probability of meeting bioequivalence criteria for extent (AUC) and rate (Cmax) of drug absorption when the absorption rate and fraction absorbed (F) were formulated either to be equivalent or to differ by 25%."( The role of metabolites in bioequivalency assessment. III. Highly variable drugs with linear kinetics and first-pass effect.
Jackson, AJ, 2000
)
0.31
" The relative bioavailability of the domestic capsule for single and multiple dose were 96% +/- 11% and 98% +/- 10%, respectively."( Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Ding, Y; Huang, DK; Jiang, ZH; Luo, JP; Luo, WX; Peng, JH; Qiu, J; Shen, JP; Sheng, LS; Zhang, YD, 1999
)
0.3
"The purpose of this study was to evaluate the relative bioavailability and bioequivalence of a test and a reference sublingual tablet each containing 5 mg of isosorbide dinitrate in healthy volunteers."( Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Daftsios, AC; Nikolaidis, N; Niopas, I, 2001
)
0.79
"From the results of the present study, it is concluded that the test and reference isosorbide dinitrate sublingual preparations are bioequivalent in both extent and rate of absorption and it can be assumed that they are therapeutically equivalent and exchangeable in clinical practice."( Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects.
Daftsios, AC; Nikolaidis, N; Niopas, I, 2001
)
0.82
" Conclusively, nipradilol, beta-blocker with nitric oxide-releasing action, in contrast to the other beta-blockers and nitric oxide donors, showed a successful anti-atherosclerotic effect through the restoration of nitric oxide bioavailability and possible interaction with oxygen radicals."( Anti-atherosclerotic effect of beta-blocker with nitric oxide-releasing action on the severe atherosclerosis.
Hayashi, T; Iguchi, A; Kano, H; Matsui-Hirai, H; Sumi, D; Thakur, NK; Tsunekawa, T, 2002
)
0.31
"1), with a relative bioavailability of 108."( [Multiple dose pharmacokinetic and bioavailability studies of oral sustained release and conventional formulations of isosorbide-5-mononitrate in healthy volunteers].
Fu, L; Huang, X; Ji, P; Wei, S; Yan, B; Zhang, Q, 1998
)
0.3
"These findings suggest that not only obesity but also a low BMI may be a risk factor for impaired endothelium-dependent vasodilation through the increased oxidative stress, leading to the reduced bioavailability of NO."( Low body mass index is a risk factor for impaired endothelium-dependent vasodilation in humans: role of nitric oxide and oxidative stress.
Chayama, K; Goto, C; Hara, K; Higashi, Y; Kimura, M; Matsuura, H; Nakagawa, K; Noma, K; Oshima, T; Sasaki, S; Yoshizumi, M, 2003
)
0.32
" 3178 +/- 769 ng x ml(-1) x h, respectively, and the relative bioavailability of 5-ISMN tablet was 105 +/- 20%."( Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Cai, L; Chen, J; Gao, KP; Jiang, XG; Lu, W; Shi, ZQ; Zhang, QZ, 2004
)
0.32
"We sought to determine if the nitric oxide (NO) donor isosorbide mononitrate (ISMN) (200 mg/kg body weight/day) decreases vascular bioavailability of superoxide in atherosclerosis."( Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate.
Kojda, G; König, I; Meyer, W; Müller, S, 2004
)
0.32
"Vascular oxidative stress limits the bioavailability of endothelial NO and promotes atherosclerosis, while NO itself exerts antioxidative effects."( Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate.
Kojda, G; König, I; Meyer, W; Müller, S, 2004
)
0.32
"These data suggest that eccentric ISMN can completely inhibit the increase of vascular bioavailability of superoxide and partially prevent intimal lesion formation and endothelial dysfunction in hypercholesterolemia."( Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate.
Kojda, G; König, I; Meyer, W; Müller, S, 2004
)
0.32
" In conclusion, the lowering of SBP by NO donation is consistent with the notion that ACTH-induced hypertension involves an impaired bioavailability or action of NO in vivo."( Nitric oxide donation lowers blood pressure in adrenocorticotrophic hormone-induced hypertensive rats.
Andrews, MC; McKenzie, KU; Schyvens, CG; Whitworth, JA; Zhang, Y, 2004
)
0.32
" Endothelial dysfunction, increased oxidative stress, and decreased bioavailability of nitric oxide (NO) also occur in heart failure."( The African American Heart Failure Trial: a clinical trial update.
Taylor, AL, 2005
)
0.33
" The hypotensive effect of isosorbid dinitrate, commonly used as a vasodilatator, was weaker at the onset of AW, being associated with the decreased bioavailability of the drug."( Responses to cardiovascular drugs during alcohol withdrawal.
Kähkönen, S,
)
0.13
" The apparently modest effect on survival observed in V-HeFT II could be explained in part by the poor hydralazine bioavailability of the tablet preparation used in this trial."( Lack of bioequivalence between different formulations of isosorbide dinitrate and hydralazine and the fixed-dose combination of isosorbide dinitrate/hydralazine: the V-HeFT paradox.
Cohn, JN; Packer, M; Sabolinski, ML; Tam, SW; Worcel, M, 2007
)
0.58
" The failure of synthesis and/or the lost of nitric oxide bioavailability is the major feature of endothelial dysfunction and key factor initiating progression of atherosclerosis."( [Endothelium and nitric oxide].
Garaliene, V, 2008
)
0.35
" Furthermore, the dog pharmacokinetics and relative bioavailability of the test formulation (5-ISMN MOTS) have been compared with the reference formulation (Imdur: 60 mg/tablet, a sustained release, SR, tablet system) following an oral single dose of 60 mg given to each of six Beagle dogs."( Development of monolithic osmotic pump tablet system for isosorbide-5-mononitrate delivery and evaluation of it in vitro and in vivo.
Bi, K; Chen, X; Duan, X; Liu, Q; Luo, G; Wang, Y; Zhang, Y, 2009
)
0.35
"1 h in vivo, which had a good consistency with the in vitro results, and the relative bioavailability was nearly 100% comparing to the normal tablets."( Design and evaluation of pH-independent pulsatile release pellets containing isosorbide-5-mononitrate.
Dai, Q; Liu, S; Liu, Y, 2009
)
0.35
" Experimental data suggests that hydralazine, given concomitantly, attenuates the development of hemodynamic tolerance to ISDN and may increase bioavailability of NO in the vasculature."( Isosorbide dinitrate/hydralazine: its role in the treatment of heart failure.
Jacob, RG; Thadani, U, 2008
)
1.79
"The objective of the present study was to develop a novel in vitro system to simulate the process of dissolution and permeation of oral solid dosage forms in vivo, and to establish a correlation between in vitro permeation and in vivo absorption that could predict the bioavailability (BA) and bioequivalence (BE) of congeneric products."( Study on dissolution and absorption of four dosage forms of isosorbide mononitrate: level A in vitro-in vivo correlation.
Gao, X; Gu, H; He, X; Ji, RF; Li, ZQ; Sun, SJ; Wang, YF; Xu, YY, 2011
)
0.37
" The relative bioavailability of the osmotic-pump tablets against the reference formulation in single and multiple dose regimens was 116."( In vitro and in vivo evaluation of novel osmotic pump tablets of isosorbide-5-mononitrate containing polyvinyl pyrrolidone (PVP) for controlled release.
Chi, Q; Du, L; Jiang, Q; Li, X; Wang, C, 2012
)
0.38
" Although not causal, endothelial dysfunction and reduced nitric oxide bioavailability are likely to play an important role in the maternal and fetal pathophysiology of this condition."( The nitric oxide pathway and possible therapeutic options in pre-eclampsia.
Everett, TR; Johal, T; Lees, CC; Wilkinson, IB, 2014
)
0.4
" The relative bioavailability of the ICR tablets compared to the reference formulation in the single and multiple dose regiments were 90."( Evaluation of novel immediate-/controlled-release tablets of isosorbide-5-mononitrate (5-ISMN): in vitro-in vivo correlation.
Du, L; Jiang, Q; Li, M; Li, X; Li, Y, 2014
)
0.4
"This study was performed to compare the pharmacokinetic properties and relative bioavailability of two isosorbide-5-mononitrate (5-ISMN) sustained-release drugs in healthy Korean subjects under fasting and fed conditions."( Pharmacokinetic properties of isosorbide-5-mononitrate under fasting and fed conditions in healthy male subjects.
Bentz, J; Chae, SW; Im, YJ; Jeon, JY; Jeong, JA; Jin, C; Kim, MG; Kim, Y; Kumke, T, 2015
)
0.42
" The pharmacokinetic study in rats demonstrated that the electrospinning fiber membrane had a higher Cmax and lower Tmax compared to the reference preparation, and the relative bioavailability of the fiber membrane was 151."( A novel application of electrospinning technique in sublingual membrane: characterization, permeation and in vivo study.
Chen, J; Cheng, B; Fan, J; Pan, W; Wang, X; Yang, X; Yu, S; Zhang, W, 2016
)
0.43
"Resveratrol (RVT) is a stilbene with a protective effect on the cardiovascular system; however, drawbacks including low bioavailability and fast metabolism limit its efficacy."( Synthesis, antiplatelet and antithrombotic activities of resveratrol derivatives with NO-donor properties.
Chin, CM; Dos Santos, JL; Dutra, LA; Guanaes, JFO; Johmann, N; Lopes Pires, ME; Marcondes, S, 2017
)
0.46
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Sublingual isosorbide dinitrate at the dosage given did not reduce infarct size in patients with inferior AMI. Sini decoction can reduce the dosage of nitroglycerin.

ExcerptRelevanceReference
" Advanced age modifies the approach to treatment; the choice of drugs and the dosage must be adjusted accordingly."( Drug therapy for cardiovascular disease in the aged.
Kennedy, RD, 1975
)
0.25
" When nifedipine dosage was decreased."( Nifedipine therapy for refractory coronary arterial spasm.
Heupler, FA; Proudfit, WL, 1979
)
0.26
"1 ng/ml) at 15 min after dosing and declined with a half-life of 30 min."( Plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations.
Assinder, DF; Chasseaud, LF; Taylor, T, 1977
)
0.71
" It is our thesis that chronic high oral dosage of ISDN saturates the intrahepatic biotransformation process, and allows high concentrations of ISDN and its metabolites to enter the systemic circulation."( Plasma concentrations of isosorbide dinitrate and its metabolites after chronic high oral dosage in man.
Berka, JF; Chisholm, AW; Iazzetta, JJ; Leung, D; Shane, SJ, 1978
)
0.56
" Quantitative comparisons were made from dose-response curves established for nitroglycerin (ng), PE nitrates, and other common organic nitrates after intrajugular administration."( Comparative vasodilator effects of nitroglycerin, pentaerythritol trinitrate and biometabolites, and other organic nitrates.
Davidson, IW; Di Carlo, FJ; Parker, JC, 1975
)
0.25
" The remarkable advantages of the drug are to be seen in its simple dosage and administration, its good tolerability, and its intrinsic retard-effect."( [Studies on the influence of Molsidomin on coronary heart disease (author's transl)].
Jansen, E; Klepzig, H, 1976
)
0.26
" Dose-response curves to nitroglycerin were constructed for 11 normotensive volunteers before and during treatment with a sustained-release formulation of isosorbide dinitrate, 80 mg, three times daily for 7 days and followed by concurrent treatment with NAC at a mean dose of 150 mg/kg/day, in divided doses, for 2 days."( Desensitization of nitrate-induced venodilation: reversal with oral N-acetylcysteine in humans.
Blaschke, TF; Hoffman, BB; Kongpatanakul, S; Vincent, J, 1992
)
0.48
" Some patients appeared to individually respond to > or = 1 nitrate preparation significantly more than to placebo, but this appeared to be unpredictable and largely independent of dosage level and route of administration."( Placebo effect of nitrate monotherapy for myocardial ischemia.
Hamer, AW, 1992
)
0.28
" An asymmetrical dosage regimen of isosorbide mononitrate has been shown to provide antianginal efficacy for at least 12 hours."( Pharmacokinetics of isosorbide mononitrate.
Abshagen, UW, 1992
)
0.28
" Two dosage regimens of sustained-release isosorbide dinitrate (ISDN) (60 mg tablet once daily vs 20 mg three times daily) were compared at steady state."( [Nycthemeral changes in plasma concentrations of active nitrate derivatives. Comparison of a single dose of LP 60mg isosobide dinitrate and LP 20mg isosobide dinitrate administered 3 times daily].
Auclert, L; Dorléac, D; Guillou, J; Olive, G; Ollivier, JP; Pello, JY, 1992
)
0.55
"The coronary vasodilator properties of isosorbide dinitrate (ISDN) are well known but the dosage remains empirical."( [Response of coronary arteries to the intracoronary injection of isosorbide dinitrate. Dose-response curve].
Bauters, C; Bertrand, ME; Lablanche, JM; Leroy, F, 1992
)
0.79
" The co-prescription of intravenous N-acetylcysteine at a dosage of 10 g/24 hours in 10 of the 19 patients did not affect the blood pressure or the response to the GTN bolus compared with the 9 other patients who had received placebo after double-blind randomisation."( [Evaluation of tolerance during intravenous administration of low dose of isosorbide dinitrate in the treatment of unstable angina].
Auclert, L; Blin, P; Guérin, C; Guérin, F; Pellois, A; Touiza, K; Weber, S, 1992
)
0.51
"To avoid the development of nitrate tolerance secondary to relatively constant elevated plasma nitrate concentrations, intermittent nitrate dosing has been advocated."( Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation.
Allgén, J; Amtorp, O; Nyberg, G; Olsson, G; Parker, JO, 1992
)
0.28
"Rats dosed orally with isosorbide dinitrate (1 mg kg-1) were exposed to smoke from standard and nicotine-reduced cigarettes for 8 min using a smoking machine."( Influence of standard and nicotine-reduced cigarette smoke on plasma concentrations of isosorbide dinitrate and its metabolites in rats.
Araki, Y; Furuno, K; Gomita, Y, 1991
)
0.81
" With both dosage regimens, the plasma ISDN concentrations increased gradually."( [Tolerance to a sustained release form of isosorbide dinitrate: comparison between 20 mg four times and 40 mg twice-daily administrations].
Aihara, T; Bando, M; Hamai, K; Hiasa, Y; Kataoka, Y; Nakai, Y; Ootani, R; Shinohara, H; Wada, T, 1991
)
0.55
" ST-depression at comparative work load at 2 h after dosing was reduced by 49% acutely after administration of IS-5-MN."( Evaluation of the antianginal and anti-ischemic efficacy of slow-release isosorbide-5-mononitrate capsules, bupranolol and their combination, in patients with chronic stable angina pectoris.
Krepp, HP, 1991
)
0.28
" Ten patients under each dosage were completely freed from attacks."( Sustained-release IS-5-MN in the treatment of coronary heart disease.
Keck, M, 1991
)
0.28
" In steady state during multiple dosing (t."( A combined single and multiple dose pharmacokinetic study of oral isosorbide-5-mononitrate in healthy volunteers.
Bron, J; De Jong, AP; Jonkman, JH; Oosterhuis, B; Storm, G; Wittebrood, AJ, 1991
)
0.28
"In a previous study, we developed a multiple-unit type of oral floating dosage system, which is a new type of floating pill composed of both an effervescent layer and a swellable membrane layer coated on sustained-release pills."( A new multiple-unit oral floating dosage system. II: In vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs.
Ichikawa, M; Kato, T; Kawahara, M; Kayano, M; Watanabe, S, 1991
)
0.48
" HPLC and TLC-densitometry are considered for the determination of 5-ISMN: lactose and pharmaceutical dosage forms."( New methods for the assay of 5-isosorbide mononitrate and its validation.
Azcona, T; Garcia de Mirasierra, M; Grau, C; Martin-Gonzalez, A; Pascual, C; Zamorano, P, 1991
)
0.28
" nitrate tolerance--was observed in approximately one fourth of the patients, and was not prevented by a twelve-hour dosing interval on isosorbide dinitrate nor a six hour transdermal nitroglycerin-free interval."( [Prolonged action nitrates in stable angina pectoris].
Eidsaunet, W; Erikssen, J; Myhre, E; Røde, R; Thaulow, E, 1991
)
0.48
" The influence of dosing interval of oral isosorbide dinitrate (ISDN), the nitrate preparation most widely used for the treatment of CHF, has not been investigated."( Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure.
Elkayam, U; Jamison, M; Johnston, JV; Kulick, D; Mehra, A; Ostrzega, E; Rahimtoola, SH; Roth, A; Shotan, A, 1991
)
0.79
" Early attenuation of hemodynamic response was demonstrated with frequent dosing (Q 4 hours and Q 6 hours) ISDN."( Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure.
Elkayam, U; Jamison, M; Johnston, JV; Kulick, D; Mehra, A; Ostrzega, E; Rahimtoola, SH; Roth, A; Shotan, A, 1991
)
0.53
"Our data demonstrate the development of tolerance and early attenuation of effect on left ventricular filling pressure with frequent oral dosing (Q 4 and Q 6 hours) with ISDN in patients with chronic CHF, which may be related to persistently elevated trough blood levels of ISDN."( Randomized study to evaluate the relation between oral isosorbide dinitrate dosing interval and the development of early tolerance to its effect on left ventricular filling pressure in patients with chronic heart failure.
Elkayam, U; Jamison, M; Johnston, JV; Kulick, D; Mehra, A; Ostrzega, E; Rahimtoola, SH; Roth, A; Shotan, A, 1991
)
0.53
" This anti-anginal effect persists during long-term treatment without the development of tolerance; once-daily treatment produces a plasma nitrate profile that is high enough to give anti-anginal protection during the daytime, but low enough during the latter part of the dosage interval to avoid the development of tolerance."( Clinical experience with Imdur in angina pectoris. A review.
Nyberg, G, 1990
)
0.28
" Isosorbide-5-mononitrate prolonged treadmill walking time 4, 8 and 12 h after morning dosing by 54, 41 and 52 s, but these changes were not significant compared to placebo."( Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
Parker, JO, 1991
)
0.5
" The data provide evidence of circadian phase-dependency in the dose-response relationship of oral IS-5-MN."( Clinical chronopharmacology of oral sustained-release isosorbide-5-mononitrate in healthy subjects.
Becker, HJ; Blume, H; Lemmer, B; Scheidel, B, 1991
)
0.28
" Long-term therapy with 3 x 20 mg of ISDN or IS-5-N daily over 4 weeks does not induce tolerance, whereas the dosage of 3 x 60 mg ISDN resp."( Pulmonary arterial pressure and working capacity as parameters for checking the development of tolerance under nitrate therapy.
Jansen, W; Tauchert, M, 1990
)
0.28
" Our results show that an oral dosage of 20 mg of 5-IM given to patients with stable angina pectoris increased the capacity and exercise tolerance delaying significantly the onset time of angina, the onset time of EKG ischemia and its decree induced by the effort up to 5 hours after its administration."( [Changes in exercise capacity and in induced ischemia with an oral dose of 5 isosorbide mononitrate in patients with stable angina pectoris].
Avila Escribano, C; Cascón Bueno, M; Diego Domínguez, M; Fernández Esteban, T; Martín Luengo, C; Nieto Ballesteros, F; Pavón Osuna, P; Santos Rodríguez, I, 1990
)
0.28
" While the organic nitrates are extremely effective in angina prophylaxis during acute therapy, there is increasing evidence that with many dosing regimens for oral and transdermal therapy, substantial attenuation of the antianginal effects develops."( Nitrate tolerance. A problem during continuous nitrate administration.
Parker, JO, 1990
)
0.28
" Many studies with oral dosing of isosorbide dinitrate or isosorbide-5-mononitrate at least three times daily have proven nitrate tolerance in patients with coronary artery disease and/or congestive heart failure."( Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.
Silber, S, 1990
)
0.77
" An important indicator for the effect achievable for a certain dose or for the necessary dosage to affect a defined reduction in ventricular filling pressures, is the magnitude of right atrial pressure."( [Nitrates in the treatment of heart failure].
Dirschinger, J; Hall, D; Rudolph, W, 1990
)
0.28
" The agent was found to be low toxic and well tolerated in a dosage form."( [Pharmacodynamics and results of a clinical trial of nitrogranulong, a new Soviet long-acting preparation of nitroglycerin].
Alibekov, SD; Belova, LF; Belozerova, OP; Ivanov, AA; Rusakova, KA; Sakovich, GS; Sokolov, SIa; Trumpe, TE, 1990
)
0.28
" These specific pathways of chemical degradation are likely to trigger off the development of nitrate tolerance if sophisticated dosage regimens are not maintained, because drugs which directly release NO like sodium nitroprusside or amylinitrite do not show this phenomenon."( Mechanisms of nitrate tolerance--influence of the metabolic activation pathways.
Noack, E, 1990
)
0.28
" In own long-term studies on 34 patients with coronary heart disease with clinical and haemodynamic evidence (pathologic increase of the end-diastolic pressure of the pulmonary arteries under ergometric load) of an exercise-induced heart insufficiency the efficacy of pentaerythril tetranitrate (PETN) and isosorbide dinitrate (ISDN) in chronic dosage titration use was tested."( [Long-term nitrate therapy in coronary heart disease--loss of effect by developing tolerance].
Dück, KD; Richard, F, 1990
)
0.45
" The dosage was similar in subsets I to IV (8."( Intravenous isosorbide-5-mononitrate in the treatment of acute myocardial infarction.
Batinić, Z; Goldner, V; Pavicić, L; Rezaković, DE; Stalec, J; Weiss, M, 1990
)
0.28
" At 12 hours, the 100-mg dosage still amounted to greater than 50% of its maximum and was significantly more marked than the 50 mg dose."( Long-acting, marked antiischemic effect maintained unattenuated during long-term interval treatment with once-daily isosorbide-5-mononitrate in sustained-release form.
Beyerle, A; Reiniger, G; Rudolph, W, 1990
)
0.28
"Repeated treadmill exercise tests were used in 20 patients with stable exercise-induced angina in order to comparatively examine various dosage forms of isosorbide-5-mononitrate (IMN) and isosorbide dinitrate (ID) during their single administration."( [A new antianginal preparation: isosorbide-5-mononitrate].
Blagodatskikh, SV; Egorov, LV; Martsevich, SIu; Metelitsa, VI; Simkhaev, LS; Slastnikova, ID, 1990
)
0.47
" In contrast, in hypertensives, the same dosage of isosorbid dinitrate decreased together systolic, diastolic mean, and pulse pressure."( Altered hemodynamic response to isosorbide dinitrate in essential hypertension.
Diebold, BE; Isnard, RN; Kando, T; Pannier, BM; Safar, ME; Safarian, AA, 1990
)
0.56
" To assess their antiplatelet properties in vivo and to compare time and dosage requirements, we infused both IS-2-MN and IS-5-MN for 30 minutes, on 2 separate days, into nine patients with stable coronary artery disease, at rates of 4 mg/hr (n = 4) and 8 mg/hr (n = 5)."( Inhibition of platelet function during in vivo infusion of isosorbide mononitrates: relationship between plasma drug concentration and hemodynamic effects.
Bernini, W; De Caterina, R; Giannessi, D; Lazzerini, G; Lombardi, M; Mazzone, A; Moscarelli, E; Weiss, M, 1990
)
0.28
" The peripheral arterial and venous effects of IS-5-MN during the first and last dosing interval were followed by changes in the finger pulse curve, standing systolic blood pressure, heart rate, and venous distensibility."( Relationship between pharmacokinetics and hemodynamic tolerance to isosorbide-5-mononitrate.
Jähnchen, E; Siefert, F; Trenk, D; Wagner, F, 1990
)
0.28
" However, in rings with denuded endothelium, pretreatment with (-)-R202-791 resulted in a rightward shift of the dose-response curve to (+)-S202-791, and a depression of the maximal contraction compared with controls."( A possible role for the endothelium in porcine coronary smooth muscle responses to dihydropyridine calcium channel modulators.
Baik, YH; Koch, WJ; Schwartz, A; Williams, JS, 1987
)
0.27
" Dose-response curves for the relaxing and cyclic guanosine monophosphate (cGMP) increasing effects of nicorandil were obtained in isolated strips of bovine coronary arteries and compared with those of other nitrovasodilatators."( Cyclic GMP in nicorandil-induced vasodilatation and tolerance development.
Holzmann, S; Kukovetz, WR, 1987
)
0.27
" For isosorbide dinitrate and isosorbide 5-mononitrate, as well as for transdermal nitroglycerin systems, interval treatment dosing regimens with maintained effectiveness documented in controlled studies have been delineated."( Effectiveness of interval nitrate therapy in angina pectoris.
Bayeric, A; Dirschinger, J; Hall, D; Reiniger, G; Rudolph, W, 1989
)
0.79
"Tolerance to arterial and venous effects is a common problem in longterm-therapy with nitrates when dosing schemes with multiple, regulary timed intervals throughout the day are applied."( [Afterload reduction by long-term nitrate therapy].
Bachmann, K; Wortmann, A, 1989
)
0.28
" Results indicate a circadian phase-dependency in the dose-response relationship of oral nitrates."( Clinical chronopharmacology of oral nitrates.
Becker, HJ; Blume, H; Grether, D; Lemmer, B; Lenhard, G; Renczes, J; Scheidel, B; Stenzhorn, G, 1989
)
0.28
" Dosing regimens with documented effectiveness in long-term controlled studies are available for both isosorbide dinitrate and isosorbide 5-mononitrate as well as for transdermal nitroglycerin systems."( [Long-term therapy with nitrates. How can continuous effectiveness be achieved?].
Beyerle, A; Dirschinger, J; Reiniger, G; Rudolph, W, 1989
)
0.49
" Captopril improved functional class (Canadian Cardiovascular Society) and reduced requirements for increased diuretic dosage at both 1 and 3 months of maintenance treatment."( Comparison of the immediate and long-term effects of captopril and isosorbide dinitrate as adjunctive treatment in mild heart failure.
Barin, E; Hoschl, R; Nelson, GI; Stokes, GS; Wilkes, NP, 1989
)
0.51
"A differential pulse polarographic method requiring little sample separation was developed for the determination of isosorbide-5-mononitrate in tablet dosage form with the standard addition technique and without interference from common excipients."( Determination of isosorbide-5-mononitrate in tablets by differential pulse polarography.
Giannellini, V; Gratteri, P; La Porta, E; Papeschi, G; Pinzauti, S, 1989
)
0.28
" Dose-response relations with regard to guanylate cyclase stimulation of organic nitrates and sodium nitrite were compared in the presence of cysteine and its closely related methylester."( Guanylate cyclase activation by organic nitrates is not mediated via nitrite.
Kukovetz, WR; Romanin, C, 1988
)
0.27
" Dose-response comparisons against nifedipine in 21 patients and against isosorbide dinitrate in 14 patients demonstrate that PN 200-110 has a similar antianginal efficacy profile to both drugs."( Efficacy of a new calcium antagonist PN 200-110 (isradipine) in angina pectoris.
Allen, J; Jackson, NC; Pool, PE; Taylor, SH, 1987
)
0.5
"Prolonged administration of nitroglycerin and its derivatives results in pharmacodynamic tolerance: although the dosage of these drugs is kept at the same level, their therapeutic effects decrease in amplitude."( [Comparative course of maintenance of the effects of nitrite derivatives and molsidomine after prolonged administration].
Degeorges, M; Weber, S, 1988
)
0.27
"Various dosing strategies to determine therapeutic effects of nitroglycerin (NTG) preparations are reviewed."( Hemodynamic attenuation and the nitrate-free interval: alternative dosing strategies for transdermal nitroglycerin.
Flaherty, JT, 1985
)
0.27
"Combinations of antianginal drugs may be used for an additive effect against angina, but also to off-set unwanted effects of one drug with another, either by direct effects or by a reduction of dosage of each drug."( Interactions of vasodilators with calcium entry- and beta-blockers in patients with coronary heart disease.
Adam, WE; Haerer, W; Henze, E; Hermann, T; Kohler, J; Kress, P; Stauch, M, 1986
)
0.27
"The action of various dosage forms of isosorbide dinitrate (ID) was studied with the help of repeated treadmill run in 28 CHD patients with stable angina of effort."( [Isosorbide dinitrate: correlations between its anti-anginal effect, dosage form and administration schedule].
Martsievich, SIu; Metelitsa, VI, 1988
)
1.46
"Because of the high efficacy of existing nitrates, alternative dosage formulations have been developed rather than new compounds."( Determination of nitrates in plasma.
Jaeger, H; Lutz, D; Michaelis, K; Salama, ZB, 1987
)
0.27
" Additionally, a discussion of which specific nitrate formulation are least likely to have tolerance associated with their use is included, such as short-acting nitrate formulations with the exception of the intravenous dosage form."( Tolerance to organic nitrates in ischemic heart disease.
Zeller, FP, 1987
)
0.27
" New nitrate delivery systems have recently become available which provide considerable dosing flexibility, further increasing the interest in this group of compounds."( Glyceryl trinitrate (nitroglycerin) and the organic nitrates. Choosing the method of administration.
Abrams, J, 1987
)
0.27
" Isosorbide dinitrate required fewer retitration episodes and less increases in dosage than nitroglycerin at 24 hours."( Effect of intravenous isosorbide dinitrate versus nitroglycerin on elevated pulmonary arterial wedge pressure during acute myocardial infarction.
Cintron, GB; Conti, CR; Glasser, SP; Linares, E; Weston, BA, 1988
)
1.5
" The method is applicable to the analysis of the diluted bulk drug and dosage forms, including sublingual, oral, chewable, and timed-release preparations."( Determination of isosorbide dinitrate in pharmaceutical products by HPLC.
Carlson, M; Snell, RP; Thompson, RD, 1988
)
0.61
" Its pharmacokinetics are linear over the dosage range likely to be used clinically."( Isosorbide 5-mononitrate pharmacokinetics.
Chasseaud, LF, 1987
)
0.27
"The hemodynamic and antianginal effects of 30 mg of isosorbide dinitrate (ISDN) were assessed in 12 patients with chronic stable angina after initial dosing and after 7 to 10 days of therapy four times daily."( Nitrate tolerance: the lack of effect of N-acetylcysteine.
Farrell, B; Lahey, KA; Parker, JO; Rose, BF, 1987
)
0.52
"This article reviews the development and pharmacokinetics of a number of new dosage formulations (e."( Various administration forms of nitrates and their possibilities.
Jonsson, UE, 1987
)
0.27
" After receiving treatment for 2 weeks with isosorbide dinitrate retard at a dosage of 2 or 3 tablets per day, only those patients continued the study who had a weekly average of 4 or more anginal attacks during this basal period."( Isosorbide-5-mononitrate and isosorbide dinitrate retard in the treatment of coronary heart disease: a multi-centre study.
Bidoggia, H, 1987
)
0.83
"One of the most promising concepts in nitrate therapy is interval therapy, a dosage scheme with marked changes of nitrate concentrations in the 24-h interval."( Circadian investigation of interval therapy with isosorbide dinitrate in coronary heart disease.
Bachmann, K; Meinhold, M; Wortmann, A, 1988
)
0.53
"The efficacy of the isosorbide mononitrate preparations ISMN-20 (elantan 20) and ISMN-50 (elantan long) and the influence of the time of dosage on the quality of life was investigated in 3624 patients with the clinical diagnosis coronary heart disease and stable angina pectoris in an open multi-center trial."( [The effect of time and dosage of isosorbide mononitrate on objective and subjective parameters in angina pectoris].
Herrmann, H; Kuhl, A; Maier-Lenz, H, 1988
)
0.27
" At the studied dosage there was a linear relationship between dose and serum concentration of ISDN and its two metabolites in the proportion of 1:6:70."( [Dose-dependent serum concentration of ISDN and its metabolites following administration of ISDN-retard. Studies under steady-state conditions].
Burkhardt, H; Deuster, U; Loew, D; Rietbrock, N, 1986
)
0.27
" This naturally long-acting metabolite in ISDN works usually with a standard dosage of 20 mg twice daily."( Oral isosorbide-5-mononitrate: pharmacokinetics and clinical efficacy.
Kanto, JH, 1987
)
0.27
" We conclude that tolerance to the clinical effects of isosorbide dinitrate develops with a sustained dosage of 30 mg four times daily, but not when the drug is given two or three times daily."( Effect of intervals between doses on the development of tolerance to isosorbide dinitrate.
Farrell, B; Lahey, KA; Moe, G; Parker, JO, 1987
)
0.75
" Isosorbide 5-mononitrate appears at least as effective as the same dosage of isosorbide dinitrate and is probably superior to the calcium antagonists."( Mononitrates as monotherapy in the prophylactic treatment of angina pectoris.
Aberg, A; Aström, H; Carlens, P; Lindström, E; Lundman, T; Nordlander, R; Nyberg, G; Rehnqvist, N; Ulvenstam, G, 1987
)
0.5
" We therefore assessed the dependence of nitrate tolerance development from the haemodynamic and anti-ischaemic effects of a slow-release tablet formulation of isosorbide dinitrate 80 mg, administered according to different daily dosage regimens in patients with angina."( The haemodynamic and anti-ischaemic effects of a single tablet of 80 mg isosorbide dinitrate in slow-release formulation and a review of nitrate tolerance.
Krause, KH; Silber, S; Theisen, K; Vogler, AC, 1987
)
0.7
" Therefore, the dependence of tolerance development on dosage intervals according to once-daily and twice-daily ingestions was assessed."( Induction and circumvention of nitrate tolerance applying different dosage intervals.
Krause, KH; Silber, S; Theisen, K; Vogel, M; Vogler, AC, 1987
)
0.27
" On the other hand a dosage regimen which leads to steady state plasma concentrations which fluctuate between 100 and 300 ng IS-5-N/ml (after 3 times daily 20 mg ISDN) showed no clinically significant loss of efficacy even after 4 weeks of application."( Nitrate therapy without loss of action by correct dosage.
Boertz, A; Bonn, R, 1986
)
0.27
" The overall hemodynamic response to nitrate administration will be modulated by the degree of sympathetic reflex discharge, the presence or absence of congestive heart failure, the dosage of administered nitrate, and the presence or absence of nitrate tolerance."( Hemodynamic effects of nitroglycerin and long-acting nitrates.
Abrams, J, 1985
)
0.27
", shorter duration of action, loss of intensity of effect) with long-term dosing in this clinical setting."( Nitrate tolerance.
Leier, CV, 1985
)
0.27
" It is appropriate that the patient's dosage of nitrates be administered with a formulation most likely to be both clinically effective and well tolerated."( Pharmacology of nitroglycerin and long-acting nitrates.
Abrams, J, 1985
)
0.27
" After a 2-week placebo period ISMN was administered in a single-blind fashion with the dosage being titrated at 2-week intervals."( Isosorbide-5-mononitrate--effective monotherapy in chronic stable angina.
Akhras, F; Jackson, G; Jefferies, S, 1985
)
0.27
" New dosing modes involving nitrate-free intervals appear to hold promise in avoiding the occurrence of tolerance."( Nitrate formulations and drug delivery systems--an overview.
Fung, HL, 1985
)
0.27
" Thus, sublingual isosorbide dinitrate at the dosage given did not reduce infarct size in patients with inferior AMI."( Isosorbide dinitrate sublingual therapy for inferior myocardial infarction: randomized trial to assess infarct size limitation.
Arribas Jimenez, A; Cascón Bueno, M; Castaño Bazo, L; Diego Dominguez, M; García Moreno, LM; Ledesma García, C; Martín Luengo, C; Pabón Osuna, P; Sala Sánchez-Castillo, A; Sánchez Hernández, J, 1985
)
2.05
" ISDN bioavailability after oral (10 mg) or sublingual dosing (10 mg) was similar (about 29%), indicating that the first-pass effect cannot be avoided by sublingual ISDN dosing."( Isosorbide dinitrate bioavailability, kinetics, and metabolism.
Galeazzi, RL; Straehl, P, 1985
)
1.71
" At conventional dosage the most important action of nitrates is a pooling of blood in the large systemic venous capacitance vessels which leads to a decrease of central venous pressure and ventricular filling pressure."( [Effect of nitrates, nitrate-like substances, calcium antagonists and beta-adrenergic receptor blockers on peripheral circulation].
Bassenge, E; Busse, R, 1982
)
0.26
" The metabolic profiles of PETN in rat urine and feces following intra-arterial and oral dosing of this organic nitrate were then re-examined."( Rapid microbial degradation of organic nitrates in rat excreta. Re-examination of the urinary and fecal metabolite profiles of pentaerythritol tetranitrate in the rat.
Fung, HL; King, SY,
)
0.13
" These concentrations are several thousand times greater than plasma levels achieved in man with therapeutic dosing of ISDN."( Effect of isosorbide dinitrate and its metabolites on rabbit atrial myocardial force-frequency relationships in vitro.
Levy, JV, 1982
)
0.67
" In 181 patients previously treated with isosorbide dinitrate (ISDN)-retard, the mean daily dosage of nitrate was reduced from 77 mg (200 mg maximum) ISDN to 45 mg (120 mg maximum) isosorbide 5-mononitrate in long-term treatment."( An open, long-term, multi-centre study of the anti-anginal efficacy and safety of isosorbide 5-mononitrate at low doses in patients with coronary heart disease.
Abshagen, U; Glocke, M; Steinorth, G; Uberbacher, HJ, 1983
)
0.53
" The 14-day therapy with elantan 20 in a dosage of 3 X 1 tabl."( [Treatment of coronary disease with elantan. Results of a multicenter study].
Haase, W; van Hasselt, P; Weiss, M, 1984
)
0.27
"Nitroglycerin bound to cellulose (Nitroglin) was investigated in patients with coronary heart disease as to the oral long-term effects in a dosage of 10 mg (n = 10) and 20 mg (n = 10) in comparison with 40 mg sustained release isosorbide dinitrate (n = 10) and placebo (n = 10)."( [Long-term effect of a new delayed-action nitroglycerin compared to isosorbide dinitrate. Double-blind hemodynamic study].
Hochrein, H; Lehmann, HU; Traue, P; Witt, E, 1983
)
0.69
"A reliable, sensitive, and specific assay for isosorbide dinitrate pentaerythritol tetranitrate, and erythrityl tetranitrate in sublingual, uncoated, sustained-release, and chewable dosage forms, using high-performance liquid chromatography, is described."( High-performance liquid chromatographic determination of the nitrate esters isosorbide dinitrate, pentaerythritol tetranitrate, and erythrityl tetranitrate in various tablet forms.
Olsen, CS; Scroggins, HS, 1984
)
0.76
" The log dose-response curve of ISDN in rabbit aortic rings was constructed in the absence and presence of three fixed concentrations of 5-ISMN (5 X 10(-6), 10(-5), and 3 X 10(-5) M)."( Effect of 5-isosorbide mononitrate on isosorbide dinitrate-induced relaxation of rabbit aortic rings.
Bennett, BM; Brien, JF; Marks, GS; Nakatsu, K; Tam, GS; Van Alstyne, K, 1984
)
0.54
"We describe two patients in whom spontaneous angina following acute myocardial infarction (postinfarction angina caused by coronary artery spasm) and worsening angina were successfully eliminated after clinical dosage of oral diltiazem, while marked sinus node suppression developed and temporary pacing was performed."( Elimination of unstable angina by diltiazem under temporary pacing.
Imamura, T; Ishikawa, T; Koiwaya, Y; Tanaka, K, 1984
)
0.27
"The relative bioavailability of isosorbide-5-mononitrate (IS-5-MN) has been determined after a 3-day period of dosing with 20 mg in standard-release reference tablets and sustained-release capsules at 12-h intervals, 40 mg in sustained-release capsules (Olicard 40 retard) at 24-h intervals and after single oral dose of 60 mg sustained-release capsules (Olicard 60 retard), in a cross-over study with 12 human subjects."( [Bioavailability of isosorbide-5-mononitrate from delayed-action formulations].
Chasseaud, LF; Cook, SC; Darragh, A; Lambe, RF; Leaf, FC; Major, RM; Taylor, T, 1984
)
0.27
" Plasma ISDN concentrations after the test sublingual dose were slightly higher after 48 hr of oral ISDN dosing (i."( Tolerance to isosorbide dinitrate: rate of development and reversal.
Fung, HL; Parker, JO; Ruggirello, D; Stone, JA, 1983
)
0.64
" Plasma concentration of ISDN and its two metabolites were measured during one dosing interval at steady state."( Plasma isosorbide dinitrate concentrations and effect after chewable and high-dose, sustained-release formulations.
Galeazzi, RL; Platzer, R; Reutemann, G, 1983
)
0.72
" Chronic dosing (40 mg orally every 6 h for 3 months) increased exercise tolerance and maintained a reduction in resting and exercise pulmonary artery and pulmonary capillary wedge pressures and pulmonary resistance, while systemic pressure and resistance returned to baseline."( Acute and chronic isosorbide dinitrate therapy in congestive heart failure: demonstration of improved exercise capacity and differing arterial and venous tolerance during chronic administration.
Huss, P; Leier, CV; Magorien, RD; Unverferth, DV, 1983
)
0.6
", heart rate, systolic and diastolic pressures were measured over 3 h after sublingual dosing and 6 h after oral dosing in both the supine and standing positions."( Effects of disease, route of administration, cigarette smoking, food intake on the pharmacokinetics and circulatory effects of isosorbide dinitrate.
Fung, HL; Parker, JO; Ruggirello, D; Stone, JA, 1983
)
0.47
" The time of onset of angina during exercise testing was also delayed in relation to the dosage given."( Dose-response relation of antianginal activity of isosorbide dinitrate.
Bussmann, WD; Kaltenbach, M; Schneider, WU; Stahl, B, 1984
)
0.52
" The presence of a longer disappearance t 1/2 after sublingual dosing suggested that the input process may be rate limiting."( Isosorbide dinitrate kinetics and dynamics after intravenous, sublingual, and percutaneous dosing in angina.
Bechtold, H; Fung, HL; Höhmann, D; Jähnchen, E; Meinertz, T; Morrison, RA; Wiegand, UW, 1983
)
1.71
" At the dosage used in this study, isosorbide dinitrate does not prevent the adverse hemodynamic effects of vasopressin."( Treatment of portal hypertension with isosorbide dinitrate alone and in combination with vasopressin.
Hallemans, R; Mélot, C; Mols, P; Naeije, R; Reding, P, 1983
)
0.81
" The presence of this prolonged disappearance phase provided at least a partial explanation for the observed accumulation of ISDN in plasma after chronic dosing on a six hourly regimen."( Prolonged plasma half-life after oral isosorbide dinitrate in patients with angina pectoris.
Fung, HL; Parker, JO, 1983
)
0.54
" At the dosage level used in this study, there was no significant difference between the two groups of patients."( [Coronary artery dilatation induced by isosorbide dinitrate injection (author's transl)].
Bertrand, ME; Delforge, MR; Lablanche, JM; Thieuleux, FA; Timant, PY, 1982
)
0.53
" The initial dosage was 33 mcg/min and dosage adjustments ranged from 16 to 130 mcg/min."( [Isosorbide dinitrate in the treatment of threatening myocardial infarction (author's transl)].
Bounhoure, JP; Cassagneau, B; Fauvel, JM; Kayanakis, JG; Puel, J; Sabot, G, 1982
)
1.17
" It was concluded that the transdermal dosage form of ISDN, which possesses a more prolonged pharmacologic effect than the oral dosage form, may be useful in the prevention and cure of angina pectoris."( [Hemodynamic effects of a transdermal formulation of isosorbide dinitrate and its pharmacokinetics in conscious dogs].
Kimura, T; Kogi, K; Saito, T; Tanaka, O, 1982
)
0.51
" 2 Significant accumulation of intact ISDN in plasma was observed after four times a day dosing at 30, 60 and 120 mg for 1 week."( Kinetics of isosorbide dinitrate and relationships to pharmacological effects.
Darke, A; Fung, HL; McNiff, EF; Parker, JO; Ruggirello, D; Thadani, U, 1981
)
0.64
" ISDN infusion with 30 min interruption between the different dosage steps."( [Influence of isosorbide dinitrate on haemodynamics and gas exchange in acute respiratory distress syndrome (author's transl)].
Draxler, V; Krenn, J; Mauritz, W; Sporn, P, 1980
)
0.62
"Asymmetric dosage regimens are used to circumvent development of nitrate tolerance and are believed to restore totally the hemodynamic responsiveness to an acute dosage of nitrates."( Early hemodynamic effects at rest with acute and chronic isosorbide dinitrate treatment in patients with ischemic heart disease.
Jørgensen, LH; Refsum, HE; Thaulow, E, 1995
)
0.54
" Furthermore, the choice of only one antiischemic drug at a fixed dosage may not be aggressive enough in suppressing ischemia completely."( [Isosorbide-5-mononitrate in silent ischemia].
Brandt, D; Dorda, W; Pichler, M; Teubl, H, 1995
)
0.29
"Eighteen patients with acute myocardial infarction (AMI) followed the same extended-release isosorbide 5-mononitrate dosage regimen as was used in the Fourth International Study of Infarct Survival (ISIS-4)."( The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
Held, P; Hornestam, B; Jonsson, UE; McClennen, W, 1995
)
0.29
"Isosorbide-5-mononitrate (IMN) concentration-antianginal effect relationships were studied in 14 coronary heart diseases patients with stable exertion-induced angina after administration of Efox (Schwarz-Pharma) as two dosage forms: routinely acting tablets (20 mg) and long-acting capsules (50 mg)."( [The relationship between the isosorbide-5-mononitrate concentration and its antianginal effect following the administration of regular and prolonged-action drug forms in patients with stenocardia of effort].
Blagodatskikh, SV; Kozyreva, MP; Kutishenko, NP; Martsevich, SIu; Metelitsa, VI; Simkhaev, LS; Slastinkova, ID; Vakulovskaia, MK,
)
0.13
" Simple, well-designed dosing schedules can avoid tolerance and rebound phenomena and can improve patient compliance."( The rationale for nitrates in angina pectoris.
Held, P; Olsson, G, 1995
)
0.29
"In vitro release tests and in vivo absorption measurements of oral cavity dosage forms of isosorbide dinitrate (ISDN) prepared from mixed polymer film systems were conducted."( Release of isosorbide dinitrate from polymer film dosage forms and absorption of this drug through the oral mucosa of rats.
Danjo, K; Kitamura, Y; Miyagawa, Y; Otsuka, A, 1994
)
0.9
" The three nitrate compounds currently available in the United States--nitroglycerin, isosorbide dinitrate, and isosorbide mononitrate--are provided in a variety of dosage forms, including sublingual, transmucosal, oral, and transdermal preparations."( The role of nitrates in coronary heart disease.
Abrams, J, 1995
)
0.51
" Appropriate dosing regimens of controlled-release formulations of isosorbide dinitrate (ISDN) and controlled-release NTG during long-term therapy have not been established."( Short and long-acting oral nitrates for stable angina pectoris.
Lipicky, RJ; Thadani, U, 1994
)
0.52
" The dosage was high, as judged by side-effects reported (mainly headache)."( Effects of treatment with oral isosorbide dinitrate on platelet function in vivo; a double-blind placebo-controlled study in patients with stable angina pectoris.
Andersson, A; Hjemdahl, P; Wallén, NH, 1994
)
0.57
"To assess the anti-anginal efficacy of eccentric dosing with a sustained-release formulation of isosorbide dinitrate (ISDN) administered twice daily in an eccentric fashion (08:00 and 14:00)."( Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris.
Baird, MG; Parker, JO, 1994
)
0.76
"Eccentric dosing with sustained-release ISDN, 40 mg given 6 h apart, provided significant improvement in exercise performance for up to 14 h during sustained therapy."( Efficacy of eccentric dosing with sustained-release isosorbide dinitrate in patients with angina pectoris.
Baird, MG; Parker, JO, 1994
)
0.54
"Asymmetric dosage regimes have been introduced to circumvent development of nitrate tolerance."( Influence of glyceryl trinitrate on venous and arterial effects of chronic, asymmetric isosorbide dinitrate treatment in patients with ischemic heart disease.
Jørgensen, LH; Refsum, HE; Thaulow, E, 1994
)
0.51
"Thirty-seven patients with chronic, stable angina pectoris were included in a randomized, double-blind cross-over study to assess the efficacy of once- and twice-daily dosage regimens of 60 mg isosorbide-5-mononitrate, in a controlled-release formulation (5-ISMN Durules, Astra)."( Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
Nordlander, R; Walter, M, 1994
)
0.29
" There was no increase in nocturnal angina during eccentric dosing with IS-5-MN."( Eccentric dosing with isosorbide-5-mononitrate in angina pectoris.
Parker, JO, 1993
)
0.29
" The formulation conforms to the total drug incorporated in the dosage form."( Controlled-release isosorbide dinitrate pellets. Part I: Design and evaluation of controlled-release capsule dosage form.
Bhat, SU; Lalla, JK, 1993
)
0.61
" The aim of the study was to determine whether or not an asymmetric dosing regimen was being followed by the patients."( Compliance as a factor in the development of nitrate tolerance: a patient investigation.
Löfdahl, P,
)
0.13
" dosing schedule) oral treatment with isosorbide-5-mononitrate (IS-5-MN; 5 mg kg-1) indicative of the induction of tolerance to GTN but not to SIN-1."( Release of nitric oxide from glyceryl trinitrate by captopril but not enalaprilat: in vitro and in vivo studies.
Mollace, V; Pistelli, A; Salvemini, D, 1993
)
0.29
" The beneficial nitrate effect can be preserved by appropriate dosing which provides a period of many hours of nitrate washout during each 24 h period."( Nitrate tolerance--problems both new and old.
Parker, JO, 1996
)
0.29
"In a randomized, double-blind, crossover study, 89 patients with stable angina pectoris were studied to compare two different dosage strategies of isosorbide-5-mononitrate (5-ISMN)."( Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas, TJ; Niemeyer, MC; van der Meulen, J; van der Wall, EE, 1996
)
0.29
"The two dosage regimens were equally efficient for the relief of angina pectoris without development of tolerance."( Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas, TJ; Niemeyer, MC; van der Meulen, J; van der Wall, EE, 1996
)
0.29
"(1) Starting on a low dosage was associated with a reduced frequency and severity of headache and did not notably influence the beneficial effect on angina pectoris."( Nitrate-induced headache in patients with stable angina pectoris: beneficial effect of starting on a low dosage. 5-ISMN headache study group.
Cleophas, TJ; Niemeyer, MC; van der Meulen, J; van der Wall, EE, 1996
)
0.29
" In patients with arterial hypertension, blood flow responses to infusions of organic nitrates were significantly impaired over the entire dose-response curve compared with those of normotensive controls (220 nmol/min GTN 13."( Impaired effectiveness of nitric oxide-donors in resistance arteries of patients with arterial hypertension.
Feelisch, M; Kelm, M; Preik, M; Strauer, BE, 1996
)
0.29
" Dosing started at 1 microgram/kg/min and was titrated up during the first 30 min of infusion, to produce a 10% reduction in diastolic blood pressure (DBP)."( Hemodynamic and humoral effects at rest and after head-up tilt tests during 24-hour infusion of a new nitrate ester, ITF 296, compared with ISDN and placebo in healthy volunteers: a double-blind, randomized, within-subject study.
Bianchini, C; Boyce, M; Johnston, A; Sardina, M; Warrington, SJ, 1995
)
0.29
"Neither dosage of isosorbide dinitrate had an effect on emptying which differed from the effect of placebo and the effects of the two dosages were the same."( Gastric emptying of semisolid meal unaltered by 3 days' administration of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate.
Bergmann, H; Schneider, C; Stacher, G; Stacher-Janotta, G; Steinringer, H, 1997
)
0.83
" The final dosage of enalapril was 40 +/- 23 mg/day of isosorbide dinitrate it was 153 +/- 127 mg/day."( Reverse remodeling in heart failure with intensification of vasodilator therapy.
Keteyian, SJ; Lesch, M; Levine, AB; Levine, TB; Narins, B, 1997
)
0.54
"Amplitude, duration, propagation velocity and onset latency of oesophageal contractions were not affected by either dosage of isosorbide dinitrate."( Effects of 3-days' intake of a sustained-release preparation of the nitric oxide donor, isosorbide dinitrate, on oesophageal motility.
Gaupmann, G; Holzäpfel, A; Schneider, C; Stacher, G; Stacher-Janotta, G; Steinringer, H, 1997
)
0.73
" The differences in the effects of the two dosage forms of IS-5-MN on painless ischemia may be explained by limited coronary reserves of anginal patients."( [The effect on painful and silent myocardial ischemia of the preparations Efox and Efox Long in patients with stenocardia of effort].
Belousov, IuB; Egorova, NA; Karasev, AV; Upnitskiĭ, AA, 1997
)
0.3
"The effect of extended-release isosorbide mononitrate (ER-ISMN) on exercise tolerance 1 hour after dosing was compared with that of placebo in a multicenter, randomized, double-blind study of 151 patients with stable effort-induced angina."( Effect of extended-release isosorbide mononitrate one hour after dosing in patients with stable angina pectoris. IMDUR Study Group.
Glasser, SP, 1997
)
0.3
"A straightforward quantitative method for gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate (IS5MN) and its related impurities such as isosorbide (IS), isosorbide diacetate (ISDA) and isosorbide 2-acetate-5-nitrate (IS2A5N) in raw materials as well as in dosage formulations is developed."( Gas chromatography-mass spectrometry determination of isosorbide 5-mononitrate and related impurities in raw materials and dosage formulations.
Agbaba, D; Comor, JJ; Marinković, VD; Milojković, SS; Nedeljković, JM; Zivanov-Stakić, D, 1997
)
0.3
" This study was conducted to determine the optimal dosage and mode of administration (intravenous bolus versus sublingual spray) of nitrates and the therapeutic goals of their use in the immediate management of unstable angina."( High-dose nitrates in the immediate management of unstable angina: optimal dosage, route of administration, and therapeutic goals.
Barash, P; Cotter, G; Faibel, H; Golik, A; Metzkor, E; Miller, R; Moshkovitz, Y; Schlezinger, Z; Shemesh, E; Simovitz, A, 1998
)
0.3
" Nitrates show drug tolerance during chronic treatment so an asymmetric dosing regimen may prevent loss of effect of nitrates."( Treatment of elderly patients with isolated systolic hypertension with isosorbide dinitrate in an asymmetric dosing schedule.
Breed, JG; Kleinjans, HA; Kragten, JA; Lustermans, FA; Starmans-Kool, MJ; Van Bortel, LM, 1998
)
0.53
"In patients with chronic stable angina, IMD provides effective antianginal prophylaxis for up to 12 hours and does not seem to be associated with rebound phenomena at the end of the dosage interval."( Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara, NS; Noble, S, 1999
)
0.3
" There is substantial evidence that this can be prevented by an adequate nitrate-free or nitrate-low period during each 24 h dosing interval."( Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
Waller, DG, 1999
)
0.3
" According to the dosage interval of isosorbide dinitrate, 66 patients with coronary heart disease were divided into group A and group B in a random, control and double-blind method."( Evaluation of nitrate tolerance in patients with coronary heart disease by vascular ultrasonography and treadmill exercise.
Liao, JT; Wang, ZH; Yu, GL; Zhuang, HP, 1999
)
0.58
"High-dosage nitrates are more effective for the management of anginal symptoms but produce more adverse effects, including development of tolerance and the zero-hour effect (rebound angina at the end of the dosing interval)."( Comparison of 50-mg and 100-mg sustained-release isosorbide mononitrate in the treatment of stable angina pectoris: effects on quality-of-life indices. Dutch Mononitrate Quality of Life (DUMQOL) Study Group.
Buunk, BP; Cleophas, TJ; Niemeyer, MG; van der Sluijs, H; van der Wall, EE; Zwinderman, AH, 1999
)
0.3
"On average, we observed a moderate increase of Q one hour after ISMO dosing (+8."( Human retinal hemodynamics following administration of 5-isosorbide mononitrate.
DuPont, J; Grunwald, JE; Iannaccone, AE, 2000
)
0.31
" dosing had the same immediate beneficial effects on LV function during exercise after a morning dose as did untreated patients."( Response to changing plasma concentrations of isosorbide-bound NO2 during acute and sustained treatment with isosorbide dinitrate in patients with coronary artery disease.
Bredesen, J; Jørgensen, LH; Refsum, HE; Thaulow, E, 2000
)
0.52
"Comparison of the two isosorbide dinitrate dosage forms--cardiket 120 mg once a day and cardiket 40 mg 3 times a day--showed that the former is superior by clinical efficiency."( [Comparison of dinitrate isosorbide retard forms in ischemic heart disease patients with stable effort angina].
Alekseeva, IA; Komar, OA; Lupanov, VP; Naumov, VG; Romasiuk, SS; Vasil'eva, NN, 2000
)
0.62
"Asymmetric dosage regimens of isosorbide mononitrate provide better antianginal efficacy and quality of life in patients with stable angina pectoris than the daily administration of multiple small doses of the compound."( Independent determinants of the efficacy of nitrate therapy.
Cleophas, TJ; Jansen, R; Niemeyer, MG; Zwinderman, AH, 2000
)
0.31
" Intermitted dosing of nitrates, as a prevention of tolerance, and the practical results of works using other pharmacologic interventions in a clinical setting are discussed in the final section of this paper."( [Evaluation of antianginal efficacy of long-term therapy with low dose isosorbide dinitrate in patients with stable angina pectoris].
Kośmicki, M; Sadowski, Z, 2000
)
0.54
" After baseline, maximal contraction of the rings was achieved using 60 mmol/l of KCl, they were exposed to increasing doses of ISDN and NTG (10-100 microg/ml), and dose-response curves were recorded."( Vasoactive response of different parts of human internal thoracic artery to isosorbide-dinitrate and nitroglycerin: an in-vitro study.
Frolkis, I; Gurevitch, J; Kramer, A; Locker, C; Mohr, R; Paz, Y; Pevni, D; Shapira, I, 2001
)
0.31
"Domestic 5-IM sustained-release capsule showed bioequivalence compared with the imported capsule and provided the same nitrate-low interval in the latter part of the 24-h dosing interval."( Pharmacokinetics of sustained-release capsule of 5-isosorbide mononitrate in 20 healthy Chinese young men.
Ding, Y; Huang, DK; Jiang, ZH; Luo, JP; Luo, WX; Peng, JH; Qiu, J; Shen, JP; Sheng, LS; Zhang, YD, 1999
)
0.3
"Protocol 1: Five patients were selected, and the dose-response of the antecubital artery was evaluated by administering Ach (0."( [Impact of high remnant-like lipoproteins on the function of peripheral arterial endothelium in patients with hyperlipidemia and normolipidemia: estimation using Doppler flow analysis].
Akutsu, H; Funada, J; Otani, T; Sekiya, M; Watanabe, K, 2001
)
0.31
" The pharmacological effect following dinitrate dosing was analyzed by a sigmoidal Emax model assuming a simple additive effect of dinitrate and mononitrate."( Stereoselective pharmacokinetics and pharmacodynamics of organic nitrates in rats.
Hatanaka, T; Ihara, K; Katayama, K; Kodera, M; Koizumi, T, 2001
)
0.31
"The study was undertaken to investigate the effects of continuous, long-term dosing with oral slow-release ISDN on the incidence of cardiac events in patients with healed myocardial infarction (MI)."( Continuous long-term dosing with oral slow-release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction.
Hayashi, T; Ikeda, A; Ishikawa, K; Kanamasa, K; Kimura, A; Takenaka, T, 2001
)
0.56
"Continuous long-term dosing with oral, slow-release ISDN does not reduce and probably increases the incidence of cardiac events among patients with healed MI."( Continuous long-term dosing with oral slow-release isosorbide dinitrate does not reduce incidence of cardiac events in patients with healed myocardial infarction.
Hayashi, T; Ikeda, A; Ishikawa, K; Kanamasa, K; Kimura, A; Takenaka, T, 2001
)
0.56
" Data including age, gender, type of medication, dosage and cost were extracted from the database of the largest health maintenance organisation (HMO) in Israel."( The prescription pattern of oral nitrates in coronary artery disease. Appropriateness and cost considerations.
Aviram, EE; Elhayani, A; Galai, N; Lifshitz, M; Paran, E; Peled, R; Reuveni, H; Sherf, M, 2001
)
0.31
"The influences of food, tablet splitting, and fractional dosing on the pharmacokinetics of a new controlled-release double-scored tablet containing 60 mg isosorbide-5-mononitrate (Monoket Multitab) were investigated in healthy male volunteers."( Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
Acerbi, D; De Bruyn, S; Deroubaix, X; Jeanbaptiste, B; Lebacq, E; Nollevaux, F; Poli, G; Stockis, A, 2002
)
0.31
" The rats were anesthetized with sodium pentobarbital 18-24 h after the last dosing with ISDN or its vehicle."( Penile erectile responses to cavernous nerve stimulation in rats are not affected by nitrate tolerance.
Adachi, H, 2002
)
0.31
"A reversed phase HPLC method using C(18) column was developed for the quantitative determination of isosorbide mononitrate (IMN) in the bulk material and extended release dosage forms."( A validated high performance liquid chromatographic method for analysis of isosorbide mononitrate in bulk material and extended release formulations.
Garg, S; Verma, RK, 2002
)
0.31
" In contrast, it is unclear whether vascular superoxide increases during eccentric administration of oral nitrates, which is a widely used therapeutic dosing regimen."( Preserved endothelial function after long-term eccentric isosorbide mononitrate despite moderate nitrate tolerance.
Kojda, G; Laber, U; Meyer, W; Müllenheim, J; Müller, S, 2003
)
0.32
" After baseline contraction of the rings, achieved using 60 mmol/L of KCl, they were exposed to increasing doses of ISDN and NTG (10 to 100 microg/ml), and dose-response curves were recorded."( Comparison of vasoactive response of left and right internal thoracic arteries to isosorbide-dinitrate and nitroglycerin: an in vitro study.
Frolkis, I; Kramer, A; Lev-Ran, O; Mohr, R; Paz, Y; Pevni, D; Shapira, I,
)
0.13
" Future studies of L-arginine in conjunction with chronic continuous ISMN dosing are warranted."( Interactions of L-arginine, isosorbide mononitrate, and angiotensin II inhibitors on arterial pulse wave.
Barin, ES; Gilfillan, KL; Kaesemeyer, WH; Stokes, GS, 2003
)
0.32
" Resistance to ID, SF in group 1 was relative and depended on dosage form of nitrates."( [Nitrates in therapy of effort angina in hypotensive patients].
Borovkova, NV; Chernov, VI; Demochko, AV; Idrisova, EM; Karpov, RS; Kladieva, EA; Shishkina, AA; Vorob'eva, EV, 2003
)
0.32
" Each consecutive dosing was separated by a washout period of 7 days."( Pharmacokinetics of three organic nitrates in Chinese healthy male volunteers.
Cai, L; Chen, J; Gao, KP; Jiang, XG; Lu, W; Shi, ZQ; Zhang, QZ, 2004
)
0.32
" Using electronic measurement, significantly greater adherence to the once daily versus the twice daily nitrate regimen in terms of dosing and timing was found."( Comparison of once daily versus twice daily oral nitrates in stable angina pectoris.
Kardas, P, 2004
)
0.32
" During a 4-hour delay of the regular morning dose of ISMN, mean systolic blood pressure was higher than with the regular ISMN dosing schedule (P<0."( Long-term effectiveness of extended-release nitrate for the treatment of systolic hypertension.
Barin, ES; Bune, AJ; Huon, N; Stokes, GS, 2005
)
0.33
" Effects of each nitrate on pulse wave reflection (augmentation index (AIx)), platelet response to adenosine di-phosphate (ADP 1 micromol l(-1)), nitroglycerine (NTG 100 micromol l(-1)) and the non-nitrate NO donor sodium nitroprusside (SNP 10 micromol l(-1)), were measured pre-dose, 4 and 8 h post dose, on three occasions: 1) at the end of a pre-nitrate phase, 2) after dosing for 7 days and 3) following 14 days of full dose therapy with either nitrate."( Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.
Chirkov, YY; Holmes, AS; Horowitz, JD; Pereira, J; Poropat, S; Willoughby, SR, 2005
)
0.33
"During Dob 2DE, side effects rates increased by dosage, the drug even induced ischemia at a dosage of 10 microg."( [Pharmacological stress echocardiography for diagnosing of viable myocardium in severe left ventricular dysfunction].
Chen, JL; Hu, FH; Wang, YW; Yang, WX; Yang, YJ; You, SJ, 2005
)
0.33
" Whereas in dippers ACE inhibitors had a super-dipping effect when dosed at night, no consistent difference in BP lowering effect on the 24-hr BP profile was found with calcium channel blockers after morning and evening dosing."( The importance of circadian rhythms on drug response in hypertension and coronary heart disease--from mice and man.
Lemmer, B, 2006
)
0.33
" As a patient-friendly, convenient, and multi-day dosing therapeutic system, the transdermal patches incorporating ISDN and BP could be promising for prevention and treatment of hypertension."( A novel transdermal patch incorporating isosorbide dinitrate with bisoprolol: in vitro and in vivo characterization.
Fu, JH; Kong, SJ; Li, L; Lu, WL; Pei, QL; Shan, Y; Su, CH; Wang, JC; Wang, L; Wang, SM; Wang, Y; Zhang, EH; Zhang, H; Zhang, Q; Zhang, S; Zhang, X; Zhao, JH, 2007
)
0.61
" In the three similar studies with oral medications dose-response curves for venoconstriction by locally infused norepinephrine were established before and 1 h, 2 h and 3 h after oral medication and ED50 values of norepinephrine were calculated."( Influence of systemically given placebo, trapidil and isosorbide dinitrate on norepinephrine-evoked hand vein constriction in healthy subjects.
Dannenberg, K; Konschak, A; Lautenschläger, C; Presek, P; Sziegoleit, W, 2007
)
0.59
" It was concluded that neural network technique could be particularly suitable in the pharmaceutical technology of time-dependent dosage forms where systems were complex and nonlinear relationships often existed between the independent and the dependent variables."( Optimization and evaluation of time-dependent tablets comprising an immediate and sustained release profile using artificial neural network.
Chen, Q; Gan, L; Gan, Y; Ma, S; Xie, H, 2008
)
0.35
" Continuous dosage of nitrates leads to the development of tolerance both to the vascular effects and to the unwanted adverse effect, headache."( Nitric oxide-induced headache may arise from extracerebral arteries as judged from tolerance to isosorbide-5-mononitrate.
Christiansen, I; Iversen, HK; Olesen, J; Tfelt-Hansen, P, 2008
)
0.35
" To select the most appropriate drug therapy for patients with heart failure, clinicians should consider results from clinical trials in specific patient populations, adverse-event profiles, tolerability, cost, and dosing regimens."( Pharmacotherapy for heart failure with left ventricular dysfunction: beyond angiotensin-converting enzyme inhibitors and beta-blockers.
Norgard, NB; Stark, JE, 2008
)
0.35
" Pharmacokinetic assessments were taken at regular intervals over 24 h after dosing on the last day of each treatment period."( Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects.
Antunes, A; Bartlett, M; Dieterich, HA; Dole, WP; Howard, D; Vaidyanathan, S; Yeh, CM, 2008
)
0.35
" Further trials with adequate PT dosing are required to determine the efficacy of combination BL+PT therapy."( Systematic review: secondary prevention with band ligation, pharmacotherapy or combination therapy after bleeding from oesophageal varices.
Cheung, J; Tandon, P; van Zanten, SV; Zeman, M, 2009
)
0.35
" Seventy-two patients (nitrate group) took isosorbide mononitrate 30 mg daily, titered to a maximal dosage of 120 mg daily for 24 weeks."( Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate.
Li, H; Wang, SX,
)
0.13
"The objective of the present study was to develop a novel in vitro system to simulate the process of dissolution and permeation of oral solid dosage forms in vivo, and to establish a correlation between in vitro permeation and in vivo absorption that could predict the bioavailability (BA) and bioequivalence (BE) of congeneric products."( Study on dissolution and absorption of four dosage forms of isosorbide mononitrate: level A in vitro-in vivo correlation.
Gao, X; Gu, H; He, X; Ji, RF; Li, ZQ; Sun, SJ; Wang, YF; Xu, YY, 2011
)
0.37
" Treatment courses were from 3 to7 days, at a dosage of 60 mL."( [Outcome study on parenterally administered shenfu in treatment of coronary heart disease].
Li, L; Shen, H; Xie, YM; Yang, J; Zhuang, Y, 2013
)
0.39
" In dose-response studies, SC activation was increased by treatment with the NO-donor drug isosorbide dinitrate (1 mmol l(-1)) or HGF (10 ng ml(-1)) to maximum activation at lower concentrations of both than in previous studies of mouse fibers."( Satellite cell activation and populations on single muscle-fiber cultures from adult zebrafish (Danio rerio).
Anderson, JE; Zhang, H, 2014
)
0.62
"We designed two Phase I studies that assessed healthy volunteers in order to evaluate the safety and to optimize the dosing of the combination of the drugs isosorbide dinitrate, a nitric oxide donor, and ibuprofen, a nonsteroidal antiinflammatory drug."( Combined isosorbide dinitrate and ibuprofen as a novel therapy for muscular dystrophies: evidence from Phase I studies in healthy volunteers.
Baldelli, S; Capetti, A; Cattaneo, D; Clementi, E; Cossu, MV; Cozzi, V; Fucile, S; Pellegrino, P, 2014
)
1.02
" The dosing regimens differed in terms of dose, number of administrations and route of administration in the different trials."( Cervical ripening before first trimester surgical evacuation for non-viable pregnancy.
Grivell, RM; Webber, K, 2015
)
0.42
" We determined the antiallodynic response of NCX1404 after acute or after 7, 14, and 21 days of repeated daily oral dosing in mice with streptozotocin (STZ)-induced painful diabetic neuropathy (PDN)."( Repeated Dosing with NCX1404, a Nitric Oxide-Donating Pregabalin, Re-establishes Normal Nociceptive Responses in Mice with Streptozotocin-Induced Painful Diabetic Neuropathy.
Almirante, N; Bastia, E; Brambilla, S; Impagnatiello, F; Ravani, A; Storoni, L; Targa, M; Varani, K; Vincenzi, F, 2016
)
0.43
"Based on this systematic review, Sini decoction can reduce the dosage of nitroglycerin,\ when compared with isosorbide dinitrate group."( Sini decoction as an adjuvant therapy for angina pectoris: a systematic review of randomized controlled trials.
Fei, Y; Wu, J; Xia, W; Yang, G; Yang, M; Yuan, D; Zhang, H; Zhang, Z, 2017
)
0.67
" Administration of ASA increased the infarct severity; however, concomitant dosing with NTG somewhat attenuated this effect."( Nitroglycerin application and coronary arteriogenesis.
Bramlage, P; Buschmann, IR; Dawid, R; Dülsner, A; Gatzke, N; Gorath, M; Güc, N; Hillmeister, P; Pagonas, N; Smith, KH, 2018
)
0.48
" The proposed sensing method was applied successfully for the analysis of nitroglycerin and isosorbide dinitrate in dosage forms within concentration range of (0."( Fluorescent sensing for some nitric oxide donors in dosage forms and biological matrices.
ElOnsy, S; Keshk, RM; Talaat, W, 2021
)
0.84
" The dosage of nitrates used for angina pectoris widely differs among individuals, and therapeutic resistance and tolerance gradually occur."( Higher than recommend dosage of sublingual isosorbide dinitrate for treating angina pectoris: a case report and review of the literature.
Cao, HY; Liu, Y; Qin, L; Song, ZK; Tang, ML; Wu, HD; Yang, S, 2021
)
0.88
"A modified in vitro-in vivo correlation (IVIVC) of the oral solid dosage forms has been proposed as a linear correlation between in vitro and in vivo dissolution."( Quantitative Assessment of the in vivo Dissolution Rate to Establish a Modified IVIVC for Isosorbide Mononitrate Tablets.
Cheng, Z; Tan, Y; Wang, L; Zhang, G; Zhang, L, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
nitric oxide donorAn agent, with unique chemical structure and biochemical requirements, which generates nitric oxide.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
nitrate esterAny member of the class of nitrates resulting from the esterification of nitric acid with an alcohol.
glucitol derivativeA hexitol derivative that is formally obtained from a glucitol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency5.62340.044717.8581100.0000AID485294
AR proteinHomo sapiens (human)Potency0.00210.000221.22318,912.5098AID743042
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency100.00003.548119.542744.6684AID743266
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (148)

Assay IDTitleYearJournalArticle
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID540216Clearance in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID226299In vitro percent nitric oxide released from the test compound was determined as the percent of nitrite (NO2-) produced in phosphate buffered saline at 1 hr2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID280837Vasodilation of phenylephrine-induced contraction in Wistar rat aorta in the presence of ODQ2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.
AID94494In vitro cell cytotoxicity was determined against KBALB cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID2911In vitro cell cytotoxicity was determined against 143B-LTK cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID1332962Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by REMA method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID226298In vitro percent nitric oxide released from the test compound was determined as the percent of nitrite (NO2-) produced in phosphate buffered saline at 16 hr2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID540219Volume of distribution at steady state in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID309710Vasodilatory effect in pig pulmonary artery assessed as inhibition of PGF2-alpha-induced contraction2007Bioorganic & medicinal chemistry letters, Nov-01, Volume: 17, Issue:21
NO donors. Part 16: investigations on structure-activity relationships of organic mononitrates reveal 2-nitrooxyethylammoniumnitrate as a high potent vasodilator.
AID1062382Induction of nitric oxide release in PBS buffer supplemented with L-cysteine, xanthine, xanthine oxidase assessed as nitrite release at 250 to 500 uM after 1 hr by Griess assay2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Design, synthesis, and evaluation of fimbrolide-nitric oxide donor hybrids as antimicrobial agents.
AID94497In vitro cell cytotoxicity was determined against KBALB-STK cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID311367Permeability coefficient in human skin2007Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22
Transdermal penetration behaviour of drugs: CART-clustering, QSPR and selection of model compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID226300In vitro percent nitric oxide released from the test compound was determined as the percent of nitrite (NO2-) produced in the present of L-cysteine in Phosphate buffer saline at 16 hr2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID701329Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate after 5 mins by Ellman's method2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID701328Selectivity ratio of IC50 for eel AChE to IC50 for equine serum BuChE2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID95393Compound was tested for in vitro nitric oxide release in the presence of 18 mM L-cysteine at 16 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1332965Cytotoxicity against mouse J774A.1 cells measured after 24 hrs by resazurin based fluorescence method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID185060Compound was tested for in vitro nitric oxide release in the presence of rat serum at 1 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID280838Vasodilation of phenylephrine-induced contraction in Wistar rat aorta in the presence of HbO22007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540214Clearance in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID701323Vasorelaxant activity in rat aortic rings assessed as reduction of norepinephrine-induced contraction2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID540218Clearance in monkey after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID2904In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1062380Antibacterial activity against Pseudomonas aeruginosa assessed as growth inhibition at 500 uM after 2 hrs by GFP reporter gene assay2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Design, synthesis, and evaluation of fimbrolide-nitric oxide donor hybrids as antimicrobial agents.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1062381Induction of nitric oxide-dependent nirS gene expression in Pseudomonas aeruginosa at 500 uM incubated for 2 hrs under dark condition by GFP reporter gene assay relative to untreated control2013Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23
Design, synthesis, and evaluation of fimbrolide-nitric oxide donor hybrids as antimicrobial agents.
AID540221Volume of distribution at steady state in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID2909In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1332966Induction of nitric oxide production assessed as nitrite level at 10'-4M measured after 1 hr in presence 1:50 molar excess of of L-cysteine by Griess reagent based spectrophotometer relative to control2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1404797Drug metabolism in pH 7.4 phosphate buffer assessed as nitric oxide release at 10'-4 M after 1 hr in presence of L-cysteine by Griess assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Discovery of phenylsulfonylfuroxan derivatives as gamma globin inducers by histone acetylation.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540217Volume of distribution at steady state in dog after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID315736Vasorelaxation activity in PGF2-alpha-precontracted pig pulmonary artery2008Journal of medicinal chemistry, Feb-28, Volume: 51, Issue:4
Synthesis and biological evaluation of NO-donor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID701324Induction of NO release in phosphate buffer assessed as inorganic nitrite level at pH 7.4 at 10'-4 M after 1.5 hrs by Griess assay in presence of L-cysteine2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1332979Selectivity index, ratio of IC50 for human MRC5 cells to MIC90 for Mycobacterium tuberculosis H37Rv ATCC 272942016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1332964Cytotoxicity against human MRC5 cells measured after 24 hrs by resazurin based fluorescence method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID67597In vitro cell cytotoxicity was determined against EMT-6 cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540215Volume of distribution at steady state in rat after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID704131Induction of nitrite release at 10'-4 M after 1 hr by Griess method in presence of L-cysteine2012Journal of medicinal chemistry, Sep-13, Volume: 55, Issue:17
Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives.
AID1332967n-octanol-water partition coefficient, log P of the compound by HPLC method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID700913AUC (0 to 24 hrs) in mouse assessed isosorbide mononitrate as at 10 mg/kg, po after 24 hrs2012Bioorganic & medicinal chemistry, Jan-15, Volume: 20, Issue:2
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1332963Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 in presence of nitric oxide scavanger PTIO after 7 days by REMA method2016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID94495In vitro cell cytotoxicity against KBALB-STK cell lines expressed in HSV-1 TK2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID95392Compound was tested for in vitro nitric oxide release in the presence of 18 mM L-cysteine at 1 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID94492In vitro cell cytotoxicity against KBALB cell line (transformed fibroblast sarcoma cell line)2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1743175Drug metabolism assessed as nitric oxide release in absence of rat plasma by Griess reagent based assay2020European journal of medicinal chemistry, Dec-15, Volume: 208Multiple biological active 4-aminopyrazoles containing trifluoromethyl and their 4-nitroso-precursors: Synthesis and evaluation.
AID2907In vitro cell cytotoxicity was determined against 143B cell line2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID185061Compound was tested for in vitro nitric oxide release in the presence of rat serum at 16 h2003Journal of medicinal chemistry, Mar-13, Volume: 46, Issue:6
Synthesis of 3'- and 5'-nitrooxy pyrimidine nucleoside nitrate esters: "nitric oxide donor" agents for evaluation as anticancer and antiviral agents.
AID1332968Selectivity index, ratio of IC50 for mouse J774A.1 cells to MIC90 for Mycobacterium tuberculosis H37Rv ATCC 272942016European journal of medicinal chemistry, Nov-10, Volume: 123Synthesis and biological activity of furoxan derivatives against Mycobacterium tuberculosis.
AID701330Inhibition of eel AChE using acetylthiocholine iodide as substrate after 5 mins by Ellman's method2012Journal of medicinal chemistry, May-10, Volume: 55, Issue:9
Tacrine-ferulic acid-nitric oxide (NO) donor trihybrids as potent, multifunctional acetyl- and butyrylcholinesterase inhibitors.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID226301In vitro percent nitric oxide released from the test compound was determined as the percent of nitrite (NO2-) produced in the present of L-cysteine in Phosphate buffer saline at 1 hr2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Design and synthesis of 3'- and 5'-O-(3-benzenesulfonylfuroxan-4-yl)-2'-deoxyuridines: biological evaluation as hybrid nitric oxide donor-nucleoside anticancer agents.
AID280836Vasodilation of phenylephrine-induced contraction in Wistar rat aorta2007Journal of medicinal chemistry, Apr-05, Volume: 50, Issue:7
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.
AID540220Clearance in human after iv administration2005Journal of pharmaceutical sciences, Jul, Volume: 94, Issue:7
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (3,395)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901504 (44.30)18.7374
1990's913 (26.89)18.2507
2000's641 (18.88)29.6817
2010's292 (8.60)24.3611
2020's45 (1.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 96.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index96.42 (24.57)
Research Supply Index8.45 (2.92)
Research Growth Index4.25 (4.65)
Search Engine Demand Index180.02 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (96.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1,078 (29.94%)5.53%
Reviews266 (7.39%)6.00%
Case Studies184 (5.11%)4.05%
Observational5 (0.14%)0.25%
Other2,068 (57.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (67)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Nitrate Effect on Exercise Capacitance and Hemodynamic Profile Prior to Fontan Failure [NCT04297241]Phase 220 participants (Actual)Interventional2019-12-12Completed
Effect of Nicorandil, Diltiazem or Isosorbide Mononitrate for Oral Antispastic Therapy After Coronary Artery Bypass Grafting Using Radial Artery Grafts - A Pilot Randomized Controlled Trial [NCT04310995]Phase 4150 participants (Actual)Interventional2020-06-02Completed
The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache. Development of a Pragmatic Migraine Model [NCT02485340]30 participants (Actual)Interventional2015-04-30Completed
Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor in Term or Post Term Pregnancies in Females With Pre-labor Rupture of Membranes [NCT03665779]Phase 3140 participants (Actual)Interventional2018-08-01Completed
A Randomized, Open Label, Balanced, Single Dose, 3-way Crossover Bioequivalence Study of Two Isosorbide -5 -Mononitrate Extended -Release Tablets 40 mg and ISMO Retard 40 mg Under Fed Conditions in Healthy Subjects [NCT03557580]Phase 112 participants (Actual)Interventional2018-04-17Completed
A Randomized, Open-label, One Dose, 2-way Crossover Study to Evaluate the Bioequivalence of Elantan SR* 60 mg in Comparison With Imdur SR* 60 mg Under Fasted and Fed Conditions in Healthy Korean Male Subjects (*Sustained Release) [NCT02101710]Phase 160 participants (Actual)Interventional2011-06-30Completed
Intravaginal Isosorbide Mononitrate in Addition to Misoprostol Versus Misoprostol Only for Induction of Labor: A Randomized Controlled Trial [NCT03523754]Phase 1/Phase 250 participants (Anticipated)Interventional2018-01-01Active, not recruiting
Study of Curative Effect Evaluation of DanLou Tablet on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072082]Phase 4440 participants (Anticipated)Interventional2017-06-30Not yet recruiting
Nitric Oxide Donor Isosorbide Mono Nitrate for Cervical Ripening in Induction of Labor [NCT03544606]Phase 3140 participants (Actual)Interventional2019-01-01Completed
Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study to Investigate Safety, Tolerability and Blood Pressure of 2.5 mg, 5.0 mg and 10 mg Vericiguat Each Given Over 14 ± 3 Days Together With Isosorbite Mononitrate (ISMN) 60 mg E [NCT03255512]Phase 141 participants (Actual)Interventional2017-08-17Completed
Prevention and Comparison of Different Forms of Administration of Nitrates in the Risk of Radial Spasm During Coronary Angiography. [NCT02258620]442 participants (Actual)Interventional2013-06-30Completed
A Four-arm, Single Dose, Two-Period, Pharmacokinetic Study of BiDil SR and IR Capsules and Commercial BiDil Tablets [NCT01587313]Phase 136 participants (Actual)Interventional2012-04-30Completed
Efficacy of Intravaginal Administration of Isosorbide Mononitrate Together With Misoprostol Versus Misoprostol Alone in Induction of Labor in Postdate Women [NCT03854383]Phase 2100 participants (Anticipated)Interventional2019-03-03Recruiting
Randomized Controlled Trial of Nitric-oxide Donor (NOD) Isosorbide Mononitrate (IMN) Versus Placebo for Induction of Labor in Pregnancies Complicated by Preeclampsia [NCT03171480]Phase 4176 participants (Actual)Interventional2017-10-30Completed
Medical Management of Late Intrauterine Death Using a Therapeutic Combination of Isosorbide Dinitrate and Oxytocin. [NCT02488642]Phase 460 participants (Actual)Interventional2008-05-31Completed
Renin-Angiotensin Aldosterone System and Fibrinolysis(RAAS) Interaction in Humans- Specific Aim 3 [NCT00685945]24 participants (Actual)Interventional2007-12-31Completed
Effect of Adding Vaginal Isosorbide Mononitrate to Misoprostol Prior to Intrauterine Device Insertion in Women Delivered Only by Elective Cesarean Section: a Randomized Double-blind Controlled Clinical Trial [NCT03587077]113 participants (Anticipated)Interventional2018-09-30Not yet recruiting
The Effect of Isosorbide Diesters Based Moisturizer on Skin Health [NCT04831892]34 participants (Actual)Interventional2021-04-12Completed
Open Monocentric Clinical Study for the Evaluation of Efficacy and Safety of 20 mg Monocordil Tablets Manufactured by Laboratórios Baldacci in Patients With Stable Angina [NCT02152579]Phase 386 participants (Anticipated)Interventional2014-07-31Not yet recruiting
Vasodilation or Loop-diuretics for Initial Treatment of Pulmonary Edema or Congestion Due to Acute Heart Failure - a Randomized Placebo-controlled Trial [NCT05276219]Phase 41,104 participants (Anticipated)Interventional2023-09-14Recruiting
Misoprostol Plus Isosorbide Mononitrate Versus Misoprostol For Termination Of Anembryonic Pregnancy [NCT02573051]Phase 2108 participants (Anticipated)Interventional2015-06-30Recruiting
Endoscopic Variceal Ligation Plus Propranolol And Isosorbide Mononitrate Versus Endoscopic Variceal Ligation Alone For Secondary Prophylaxis Of Variceal Bleeding: A Randomized Controlled Trial [NCT00766805]177 participants (Actual)Interventional2002-10-31Completed
Uterine Artery Doppler Changes After Vaginal Administration of Isosorbide Mononitrate In Patients With Unexplained Recurrent Pregnancy Loss [NCT05341856]Early Phase 160 participants (Anticipated)Interventional2022-05-01Not yet recruiting
Misoprostol Versus Effox (Individually or in Combination) as Cervical Ripening Agent Prior to 1st Trimesteric Surgical Evacuation [NCT02738177]Phase 290 participants (Anticipated)Interventional2015-11-30Recruiting
A Randomized, Double-blind, Placebo Controlled Study (DANHEART): Hydralazine-ISDN in Patients With Chronic Heart Failure - Hydralazine Heart Failure Trial (H-HeFT) and Metformin in Patients With Chronic Heart Failure and Diabetes or Insulin Resistance - M [NCT03514108]Phase 41,500 participants (Anticipated)Interventional2018-03-01Recruiting
Treatment of Orthostatic Intolerance [NCT00262470]Phase 1/Phase 2150 participants (Anticipated)Interventional1997-04-30Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled, 2-Part Study to Evaluate the Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis in Obese Patients With Hypertension [NCT00871871]Phase 164 participants (Actual)Interventional2009-03-31Completed
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO) [NCT00803634]Phase 3117 participants (Actual)Interventional2008-12-31Completed
Ocular Hemodynamic Effects of Nitrovasodilators in Healthy Subjects [NCT00810381]14 participants (Actual)Interventional1999-01-31Completed
Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache [NCT04217668]58 participants (Actual)Interventional2019-12-02Completed
Effect of Organic Nitrates and Hydralazine on Wave Reflections and Left Ventricular Structure and Function in Heart Failure With Preserved Ejection Fraction [NCT01516346]Phase 244 participants (Actual)Interventional2012-01-31Completed
Effect of Pioglitazone on Insulin Resistance, Progression of Atherosclerosis and Clinical Course of Coronary Heart Disease [NCT03011775]Phase 443 participants (Actual)Interventional2012-11-30Completed
[NCT00000478]Phase 30 participants Interventional1990-11-30Completed
Targeting Wave Reflections to Improve Left Ventricular Hypertrophy, Fibrosis and Myocardial Function in Hypertension [NCT01961453]Phase 20 participants (Actual)Interventional2013-08-31Withdrawn(stopped due to Funding)
Comparison of Short-term Efficacy of Furosemide, Isosorbide Dinitrate and Their Combination in Patients With Acute Decompensated Heart Failure: A Randomized Controlled Trial [NCT02649998]0 participants (Actual)Interventional2017-01-31Withdrawn(stopped due to Lack of funding)
Influence of Nitrates on Bone Remodeling and Endothelial Function in Patients With Type 2 Diabetes Mellitus. [NCT02011620]Phase 40 participants (Actual)Interventional2014-10-31Withdrawn(stopped due to The sponsor was no longer in a position to sponsor a CTIMP. Study did not open.)
the Effect of Vaginal Isosorbide Mononitrate Administration in Reducing Pain During Cooper Intrauterine Device Insertion in Nulliparous Women : a Randomized Controlled Trial [NCT04312048]Phase 3110 participants (Actual)Interventional2020-04-15Completed
Safety and Efficacy of the Effect of Isosorbide Mononitrate in Reducing Pain During Levonorgestrel-releasing Intrauterine Device Insertion in Adolescents and Young Women [NCT04311658]Phase 388 participants (Anticipated)Interventional2020-03-30Not yet recruiting
Chinese People's Liberation Army General Hospital [NCT02718521]400 participants (Anticipated)Interventional2016-03-31Active, not recruiting
Nitric Oxide Donors for Treatment of Isolated Oligohydramnios: A Pilot Study [NCT02712125]Phase 2/Phase 3100 participants (Actual)Interventional2013-08-31Completed
Pharmacokinetics, Pharmacodynamics and Safety Comparative Trial of Isosorbide Mononitrate Gel in Participants With Anal Fissure and Healthy Volunteers. [NCT02667535]Phase 10 participants (Actual)Interventional2017-07-31Withdrawn(stopped due to Study has been cancelled and it has not been initiated.)
Pain Perception, Headache Provocation and Multiomics of People Who Are Unable to Have Headache [NCT04218760]58 participants (Actual)Interventional2019-10-10Completed
Efficacy and Safety of Chinese Herbal Medicine Wen Xin Granules for the Treatment of Unstable Angina Pectoris With Yang Deficiency and Blood Stasis Syndrome: Study Protocol for a Randomized Controlled Trial [NCT04661709]Phase 4502 participants (Anticipated)Interventional2021-03-01Not yet recruiting
A Double-Blind, Randomized, Placebo-Controlled, 5-Period Crossover Study to Evaluate the Effects of a Single Dose of Losartan, a Single Dose of Isosorbide Mononitrate (ISMN), and Single Doses of Losartan + ISMN on Central Blood Pressure Measurements in Mi [NCT00943852]Phase 113 participants (Actual)Interventional2006-08-31Completed
An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg [NCT01418534]Phase 10 participants InterventionalCompleted
An Open Label, Randomized, Two Treatment, Two Sequence, Two Period, Cross-over, Single-dose Comparative Oral Bioavailability Study of Isosorbide Mononitrate 120 mg ER Tablets (Test) of Torrent Pharmaceuticals Ltd., India and Isosorbide Mononitrate 120 mg [NCT01418547]Phase 10 participants InterventionalCompleted
Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response. [NCT00450164]Phase 450 participants Interventional2000-11-30Completed
LACunar Intervention (LACI-2) Trial-2: Assessment of Safety and Efficacy of Cilostazol and Isosorbide Mononitrate to Prevent Recurrent Lacunar Stroke and Progression of Cerebral Small Vessel Disease. [NCT03451591]Phase 2/Phase 3363 participants (Actual)Interventional2018-01-08Completed
Open, Randomized, 3 Period Cross-over Design, in Healthy Volunteers to Compare the Pharmacokinetics Profiles of 3 Treatments: ISO 20, IBU 200 and IBU Plus ISO Combinations (200 + 20) Administered Per os as Single Doses [NCT01478022]Phase 112 participants (Actual)Interventional2011-10-31Completed
Phase I Clinical Trial to Evaluate the Pharmacokinetic Profile of a Formulation With Isosorbide Mononitrate 0.5% Gel - Manufactured by Sanus Pharmaceutical Ltda, to Intra Anal Application in Healthy Males and Females' Subjects [NCT04729088]Phase 10 participants (Actual)Interventional2020-12-20Withdrawn(stopped due to The sponsor will no longer develop the experimental drug.)
A Randomized Double-blind Placebo-controlled Clinical Trials of the Blood-quickening Stasis-transforming Formula Quick-Acting Heart Reliever for Patients With Moderate Coronary Stenosis [NCT01513070]Phase 4120 participants (Anticipated)Interventional2012-04-30Completed
A Prospective, Placebo-controlled, Double-blind, Randomized Study to Compare Hydralazine-isosorbide-dinitrate(HYIS) Versus Placebo on Top of Std Care in African Patients With Acute Heart Failure (AHF) and Left Ventricular Dysfunction [NCT01822808]Phase 3500 participants (Anticipated)Interventional2013-01-31Active, not recruiting
Estimation of the Long Term Effectiveness of Routine Use of Cardiac Shock Wave Therapy in the General System of Noninvasive, Invasive, and Surgical Treatment of Ischemic Heart Disease in the Conditions of a Large General City Hospital [NCT01631409]0 participants (Actual)Observational2013-09-30Withdrawn(stopped due to The study has been withdrawn due to organizational problems)
One-year Outcome of Intensive Versus Standard Blood Pressure Treatment in Non-ST Elevation Acute Coronary Syndrome: A Randomised Controlled Trial [NCT02135315]1,500 participants (Actual)Interventional2014-03-31Completed
Measuring Response of Adding Isosorbide Mononitrate to Misoprostol in Induction of Second Trimester Abortion [NCT03407521]Phase 460 participants (Actual)Interventional2017-04-12Completed
Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction [NCT02053493]Phase 2110 participants (Actual)Interventional2014-04-30Completed
Randomized, Open-Label, Daily Dose, 2-sequence, 2-way Crossover Pharmacodynamic and Pharmacokinetic Study of BiDil XR Capsules and Commercial BiDil Tablets in Self-identified Black Patients, Who Are Slow Acetylators, With Heart Failure [NCT02522208]Phase 112 participants (Actual)Interventional2015-09-30Completed
Efficacy of the Combination of Isosorbide Dinitrate Spray and Chitosan in Diabetic Foot Ulcers [NCT02789033]Phase 368 participants (Actual)Interventional2015-06-30Completed
Randomized Clinical Trial of Cervical Ripening and Labor Induction Using Stepwise Oral Misoprostol With or Without Intravaginal Isosorbide Mononitrate [NCT00374621]156 participants (Actual)Interventional2006-09-30Completed
Preventing Cognitive Decline and Dementia From Cerebral Small Vessel Disease [NCT02481323]Phase 257 participants (Actual)Interventional2016-03-31Completed
Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate to Prevent Post-ERCP Pancreatitis: a Multicentre, Non-inferiority, Double-blind, Randomised Trial [NCT04425993]2,700 participants (Actual)Interventional2020-07-01Active, not recruiting
Isosorbide Mononitrate and Misoprostol in Induction of Labour [NCT04482881]Early Phase 1130 participants (Anticipated)Interventional2020-07-21Not yet recruiting
Non-inferiority Trial Comparing Pharmacological Prevention Alone Versus Pancreatic Stents Plus Pharmacological Prevention to Prevent Post-ERCP Pancreatitis [NCT02368795]400 participants (Anticipated)Interventional2015-02-28Recruiting
Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury [NCT04051957]Phase 29 participants (Actual)Interventional2019-09-26Terminated(stopped due to Delays due to COVID and loss of research coordinator.)
Study of Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization on the Basis of Western Medicine Therapy [NCT03072121]Phase 4440 participants (Anticipated)Interventional2017-06-30Not yet recruiting
Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study [NCT02343393]Phase 3100 participants (Anticipated)Interventional2015-01-31Recruiting
Prospective Randomized Vehicle-Controlled, Double-Blind Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal [NCT05688735]40 participants (Anticipated)Interventional2023-04-20Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00685945 (3) [back to overview]Forearm Blood Flow (FBF)
NCT00685945 (3) [back to overview]Net Glucose Uptake
NCT00685945 (3) [back to overview]Net Tissue-type Plasminogen Activator (t-PA) Release
NCT00803634 (11) [back to overview]Percentage of Patients With at Least One Episode of SBP < 90 mm Hg During Study Drug Administration (up to 96 Hours)
NCT00803634 (11) [back to overview]Change From Baseline in Dyspnea (Measured By VAS) at Each Time Point
NCT00803634 (11) [back to overview]Number of Patients That Require Intubation During Study Drug Administration up to 96 Hours
NCT00803634 (11) [back to overview]Percentage Falling Below Lower Limit of SBP Target Range at Any Time During Study
NCT00803634 (11) [back to overview]Percentage Falling Below Lower Limit of SBP Target Range Within First 30 Minutes
NCT00803634 (11) [back to overview]Percentage of Patients Who Received Any Alternative IV Antihypertensive Drug at Any Time During Study Drug Treatment
NCT00803634 (11) [back to overview]Percentage Reaching Prespecified Target Range Without Falling Below Lower Limit of Target Range Within First 30 Minutes
NCT00803634 (11) [back to overview]Percentage to First Achieve Initial Prespecified SBP Target Range [≥20 mm Hg and ≤40 mm Hg Apart] and 15% Reduction From Baseline Within First 30 Minutes
NCT00803634 (11) [back to overview]SBP Area Under the Curve (AUC) Outside Prespecified Target Range
NCT00803634 (11) [back to overview]Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes
NCT00803634 (11) [back to overview]Time to Use Other IV Antihypertensives During the Study Drug Administration
NCT00871871 (7) [back to overview]Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants Who Had Normal Glucose Tolerance (NGT)
NCT00871871 (7) [back to overview]Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Fasting Glucose (IFG)
NCT00871871 (7) [back to overview]Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT)
NCT00871871 (7) [back to overview]Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Fasting Glucose (IFG)
NCT00871871 (7) [back to overview]Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Glucose Tolerant (IGT)
NCT00871871 (7) [back to overview]Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Normal Glucose Tolerant (NGT)
NCT00871871 (7) [back to overview]Part II: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state
NCT00943852 (2) [back to overview]Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg
NCT00943852 (2) [back to overview]Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo
NCT01516346 (5) [back to overview]Early Diastolic Mitral Annular Velocity
NCT01516346 (5) [back to overview]LV Mass
NCT01516346 (5) [back to overview]Myocardial Extracellular Volume Fraction
NCT01516346 (5) [back to overview]Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)
NCT01516346 (5) [back to overview]Wave Reflection Magnitude
NCT02053493 (17) [back to overview]Arbitrary Accelerometry Units (AAU) (Phase I)
NCT02053493 (17) [back to overview]Arbitrary Accelerometry Units (AAU) (Phase II)
NCT02053493 (17) [back to overview]Borg Score During 6 Minute Walk Test (Phase II)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Area Under the Curve (Phase I)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Area Under the Curve (Phase II)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Hours Active Per Day (Phase I)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Hours Active Per Day (Phase II)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Slope of Daily Average (Phase I)
NCT02053493 (17) [back to overview]Improvement in Daily Activity - Slope of Daily Average (Phase II)
NCT02053493 (17) [back to overview]Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase I)
NCT02053493 (17) [back to overview]Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase II)
NCT02053493 (17) [back to overview]N-terminal Pro-B-type Natriuretic Peptide Level (Phase I)
NCT02053493 (17) [back to overview]N-terminal Pro-B-type Natriuretic Peptide Level (Phase II)
NCT02053493 (17) [back to overview]Six Minute Walk Distance (Phase I)
NCT02053493 (17) [back to overview]Six Minute Walk Distance (Phase II)
NCT02053493 (17) [back to overview]Patient Preference for Isosorbide Mononitrate Treatment at the End of Study.
NCT02053493 (17) [back to overview]Borg Score During 6 Minute Walk Test (Phase I)
NCT02789033 (1) [back to overview]Biopsies
NCT03011775 (17) [back to overview]Coronary Artery Bypass [Coronary Revascularization]
NCT03011775 (17) [back to overview]Safety and Tolerability 3
NCT03011775 (17) [back to overview]Safety and Tolerability 1
NCT03011775 (17) [back to overview]Safety and Tolerability 4
NCT03011775 (17) [back to overview]Thickness of the Intima-media Complex
NCT03011775 (17) [back to overview]Systemic Inflammation Level
NCT03011775 (17) [back to overview]Percutaneous Coronary Intervention [Coronary Revascularization]
NCT03011775 (17) [back to overview]Cardiovascular Hospitalization
NCT03011775 (17) [back to overview]Carotic Atherosclerotic Lesions
NCT03011775 (17) [back to overview]Сardiovascular Death
NCT03011775 (17) [back to overview]Diameter of Stenosis [Carotic Atherosclerotic Lesions]
NCT03011775 (17) [back to overview]Level of Insulin Resistance 1
NCT03011775 (17) [back to overview]Level of Insulin Resistance 2
NCT03011775 (17) [back to overview]Lipid Metabolism 1
NCT03011775 (17) [back to overview]Lipid Metabolism 2
NCT03011775 (17) [back to overview]Lipid Metabolism 3
NCT03011775 (17) [back to overview]Safety and Tolerability 2
NCT03171480 (2) [back to overview]Cesarean Delivery Rate
NCT03171480 (2) [back to overview]Placental Abruption, Use of IV Antihypertensive Drug, Maternal Hypotension, Uterine Hyperstimulation and Meconium Stained Fluid
NCT04051957 (18) [back to overview]Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With a Reduction in Urine Protein Creatinine Ratio (UPC) of > 500 mg/Day From That Measured Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04051957 (18) [back to overview]Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Heart Rate Response
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Respiratory Rate Response
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Maximal Exercise Capacity VO2 Max
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Liver Stiffness Levels
NCT04297241 (6) [back to overview]Effect of Isosorbide Dinitrate on Central Venous Pressure
NCT04297241 (6) [back to overview]Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period.

Forearm Blood Flow (FBF)

Forearm blood flow was measured by strain gauge plethysmography (NCT00685945)
Timeframe: During and after each study drug administration

,,,
Interventionml/min/100ml (Mean)
FBF (bradykinin 0 ng/min)FBF (bradykinin 50ng/min)FBF (bradykinin 100ng/min)FBF (bradykinin 200 ng/min)
Control4.037.0213.1717.74
Isosorbide + L-NMMA + Control2.184.736.839.91
L-NMMA + Control2.365.168.6711.21
Sildenafil + L-NMMA + Control2.805.879.1312.92

[back to top]

Net Glucose Uptake

Individual net reuptake rates at each time point were calculated by the following formula: net uptake = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of glucose in the brachial vein and artery, respectively. (NCT00685945)
Timeframe: At baseline and after maximum dose of bradykinin

,,,
Interventionmicrogram/min/100ml (Mean)
Net glucose uptake (bradykinin 0 ng/min)Net glucose uptake (bradykinin 200 ng/min)
Control-79.95-319.85
Isosorbide + L-NMMA + Control-71.4-163.233
L-NMMA + Control-74.36-142.86
Sildenafil + L-NMMA + Control-67.3-125.32

[back to top]

Net Tissue-type Plasminogen Activator (t-PA) Release

Individual net t-PA release at each time point were calculated by the following formula: net release = (Cv-CA) x {FBF x [101-hematocrit/100]}, where Cv and CA represent the concentration of t-PA in the brachial vein and artery, respectively. (NCT00685945)
Timeframe: During and after each study drug administration

,,,
Interventionng/min/100ml (Mean)
Net t-PA release (bradykinin 0ng/min)Net t-PA release (bradykinin 50ng/min)Net t-PA release (bradykinin 100ng/min)Net t-PA release (bradykinin 200ng/min)
Control0.241.0211.8130.03
Isosorbide + L-NMMA + Control-0.383.1415.9045.32
L-NMMA + Control0.593.6522.1039.90
Sildenafil + L-NMMA + Control0.292.4618.4837.39

[back to top]

Percentage of Patients With at Least One Episode of SBP < 90 mm Hg During Study Drug Administration (up to 96 Hours)

The percent of patients with at least one episode of SBP <90 mm Hg was calculated as the number of mITT patients who had at least one episode of SBP<90 mm Hg during study drug administration up to 96 hours divided by mITT patients, and multiplied by 100 for each treatment group. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine5.9
Standard of Care1.9

[back to top]

Change From Baseline in Dyspnea (Measured By VAS) at Each Time Point

A validated visual analog scale (VAS) with a horizontal ruler showing increments from 0 to 100 mm with 0 = Best and 100 = Worst was used. The test was asked from the patient's perspective and had to be administered with patient sitting. Relative change in VAS from baseline is the value at each time point minus the baseline value. Relative change from baseline was summarized descriptively (with associated two-tailed 95% CIs of the mean values) at 15, 30 and 45 minutes and at 1, 2, 3 hours and 12 hours, and 1 hour post termination of study drug treatment. (NCT00803634)
Timeframe: Baseline (immediately prior to study drug administration) through 1 hour after study drug termination

,
Interventionmillimeters (mm) (Mean)
Baseline Through Initial 15 Min- CLV n=44;SOC n=38Baseline Through Initial 30 Min- CLV n=43;SOC n=39Baseline Through Initial 45 Min- CLV n=43;SOC n=39Baseline Through Initial 1 H- CLV n=41;SOC n=38Baseline Through Initial 2 H- CLV n=29;SOC n=29Baseline Through Initial 3 H- CLV n=14;SOC n=22Baseline Through Initial 12 H- CLV n=0;SOC n=7Baseline Through 1 H Post Drug- CLV n=41;SOC n=33
Clevidipine-18.6-28.8-37.1-43.6-45.2-47.9NA-50.1
Standard of Care-16.1-22.8-27.9-34.6-35.3-40.5-57.9-50.1

[back to top]

Number of Patients That Require Intubation During Study Drug Administration up to 96 Hours

The number of patients requiring intubation was calculated based on the total number of mITT patients. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPatients (Number)
Clevidipine0
Standard of Care0

[back to top]

Percentage Falling Below Lower Limit of SBP Target Range at Any Time During Study

The percentage of patients in whom the SBP fell below the lower limit of the prespecified target range at any time during the entire study drug treatment period (up to 96 hours) was calculated within each treatment group using the number of mITT patients achieving the endpoint divided by the number of mITT patients and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine68.2
Standard of Care70.7

[back to top]

Percentage Falling Below Lower Limit of SBP Target Range Within First 30 Minutes

The percentage of patients in whom the SBP fell below the lower limit of the prespecified target range at any time during the first 30 minutes was calculated within each treatment group using the number of mITT patients achieving the endpoint divided by the number of mITT patients and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine34.1
Standard of Care2.4

[back to top]

Percentage of Patients Who Received Any Alternative IV Antihypertensive Drug at Any Time During Study Drug Treatment

The percentage of patients who received any alternative IV antihypertensive drug at any time during the study drug treatment period (up to 96 hours) was calculated using mITT patients within each treatment group. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine15.9
Standard of Care51.2

[back to top]

Percentage Reaching Prespecified Target Range Without Falling Below Lower Limit of Target Range Within First 30 Minutes

The percentage of patients reaching this endpoint was calculated within each treatment group using the number of mITT patients reaching the endpoint divided by the number of mITT patients, and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine45.5
SOC IV Therapy51.2

[back to top]

Percentage to First Achieve Initial Prespecified SBP Target Range [≥20 mm Hg and ≤40 mm Hg Apart] and 15% Reduction From Baseline Within First 30 Minutes

Analysis of the percentage of patients achieving both components of this composite endpoint (attainment of the initial prespecified SBP target range and a 15% reduction in SBP from baseline) was calculated within each treatment group using the number of mITT patients achieving the SBP reduction goal divided by the number of mITT patients, and multiplied by 100. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine70.5
Standard of Care36.6

[back to top]

SBP Area Under the Curve (AUC) Outside Prespecified Target Range

The magnitude and duration of SBP excursions was calculated as the area under the curve (AUC) for each patient, using the trapezoidal rule, related to time (in minutes) that each patient's SBP was outside the target range. AUC was determined based on data collected from the initiation of study medication through the end of monotherapy treatment up to 96 hours, normalized per hour, and expressed as mmHg × minute/hour. (NCT00803634)
Timeframe: Initiation of study drug through end of monotherapy (up to 96 hours)

Interventionmm Hg x min/h (Mean)
Clevidipine494.96
Standard of Care966.15

[back to top]

Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes

Time to first achieve the initial pre-specified systolic blood pressure (SBP) target range and a 15% SBP reduction from baseline is the time in minutes between the initiation of study medication and the time the patient first achieved both components. Median time was estimated using Kaplan Meier method. 95% two-sided confidence interval of the median time is from 'Simon and Lee, 1982'. If patients did not reach both components within 30 minutes from the initial treatment with study medication, or another antihypertensive agent was administered, the patient was censored at 30 minutes or the time when another antihypertensive agent is given, whichever came first. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionMinutes (Median)
Clevidipine15.0
Standard of CareNA

[back to top]

Time to Use Other IV Antihypertensives During the Study Drug Administration

The length of time to use other IV antihypertensive agents was defined as the duration in hours from the initiation of study drug through the time when any other concomitant IV antihypertensive agent was administered, thus, representing the time period without use of any other concomitant IV antihypertensive agent. Median time to use other IV antihypertensive agents was obtained using Kaplan-Meier method. If a patient did not receive any concomitant IV antihypertensive during the 96-hour treatment period, this patient was considered censored at 96 hours. If study drug was stopped less than 96 hours and the patient has no concomitant IV antihypertensive agent, the patient was considered censored when study drug was stopped. (NCT00803634)
Timeframe: Initiation of study drug through any other concomitant IV antihypertensive agent administered, up to 96 hours

InterventionHours (Median)
ClevidipineNA
Standard of Care5.7

[back to top]

Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants Who Had Normal Glucose Tolerance (NGT)

Steady state was defined as 90-120 minutes post-dose. NGT participants (FPG <100 mg/dL & 2 hour plasma glucose (PG) <140 mg/dL during a 75g oral glucose tolerance test (OGTT) at screening) were neither Impaired Glucose Tolerant (IGT) nor Impaired Fasting Glucose (IFG). IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. IFG was defined as FPG between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Interventionng/minute (Least Squares Mean)
Hydrochlorothiazide (HCTZ)5.54
Hydrochlorothiazide (HCTZ) Placebo5.01

[back to top]

Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Fasting Glucose (IFG)

Steady state was defined as 90-120 minutes post-dose. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Interventionng/minute (Least Squares Mean)
Hydrochlorothiazide (HCTZ)5.60
Hydrochlorothiazide (HCTZ) Placebo4.50

[back to top]

Part I: Change in Insulin Secretion at Steady-state Compared to Placebo in Participants With Impaired Glucose Tolerance (IGT)

Steady state was defined as 90-120 minutes post-dose. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Interventionng/minute (Least Squares Mean)
Hydrochlorothiazide (HCTZ)3.44
Hydrochlorothiazide (HCTZ) Placebo3.55

[back to top]

Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Fasting Glucose (IFG)

Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IFG was defined as fasting plasma glucose (FPG) between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Hydrochlorothiazide (HCTZ)0.038
Hydrochlorothiazide (HCTZ) Placebo0.037

[back to top]

Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Impaired Glucose Tolerant (IGT)

Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. IGT was defined as a 2 hour plasma glucose >= 140 and <= 199 mg/dL during a 75g oral glucose tolerance test at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Hydrochlorothiazide (HCTZ)0.061
Hydrochlorothiazide (HCTZ) Placebo0.045

[back to top]

Part I: Change in the Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady State in Participants With Normal Glucose Tolerant (NGT)

Steady state was defined as 90-120 minutes post-dose. The ratio was the measure of the quantity of glucose disposed per unit of plasma insulin concentration (PIC). Approximate PIC was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals, time = 90, 100, 110, and 120 minutes. NGT participants (FPG <100 mg/dL & 2 hour PG <140 mg/dL during a 75g OGTT at screening) were neither IGT nor IFG at screening. IGT - defined as a 2 hour PG >= 140 and <= 199 mg/dL during a 75g OGTT at screening. IFG - defined as FPG between 100 and 125 mg/dL at screening. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Hydrochlorothiazide (HCTZ)0.045
Hydrochlorothiazide (HCTZ) Placebo0.042

[back to top]

Part II: Ratio of Whole Body Glucose Disposal to Plasma Insulin at Steady-state

Steady state was defined as 90-120 minutes post-dose. The ratio was the quantity of glucose disposed by the body per kg body weight per minute at steady state divided by the approximate steady state plasma insulin concentration. The approximate steady state plasma insulin concentration was estimated by the time-weighted average of the insulin concentration measured at 10 minute intervals in which time = 90, 100, 110, and 120 minutes. (NCT00871871)
Timeframe: 90 -120 minutes post-dose

Intervention(mg/kg/minute)/(µIU/mL) (Least Squares Mean)
Isosorbide Mononitrate (ISMN)0.040
Isosorbide Mononitrate (ISMN) Placebo0.044

[back to top]

Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg Plus ISMN 60 mg Versus Single Dose of Losartan 100 mg

The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P = pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline. (NCT00943852)
Timeframe: Baseline and 10 hours postdose

InterventionPercent Change (Least Squares Mean)
Losartan 100 mg + ISMN 60 mg-24.9
Losartan 100 mg-1.8

[back to top]

Mean Augmentation Index Percent Change From Baseline After Single Doses of Losartan 100 mg + ISMN 60 mg Versus Single Dose of Placebo

"The augmentation index (AIx) is defined as the ratio of augmentation (Δ P) to central pulse pressure and expressed as percent. AIx = (ΔP/PP) x 100, where P =~pressure and PP = Pulse Pressure. A mathematical transfer function translated the peripheral wave form into a central waveform using an FDA approved process based on directly recorded arterial pressure values. The mean AIx for each subject was estimated as a time-weighted average over the 10-hour post dose observation period and expressed as a change from baseline." (NCT00943852)
Timeframe: Baseline and 10 hours postdose

InterventionPercent Change (Least Squares Mean)
Losartan 100 mg + ISMN 60 mg-24.9
Placebo-1.3

[back to top]

Early Diastolic Mitral Annular Velocity

Diastolic mitral annular velocity measured at the basal septal mitral annulus (NCT01516346)
Timeframe: 24 weeks

Interventioncm/s (Mean)
Isosorbide Dinitrate6.8
Isosorbide Dinitrate + Hydralazine7.3
Placebo6.5

[back to top]

LV Mass

LV mass measured by MRI, in grams normalized to height in meters raised to the 1.7 power (m^1.7) (NCT01516346)
Timeframe: 24 weeks

Interventiongrams / meters ^1.7 (Mean)
Isosorbide Dinitrate68.2
Isosorbide Dinitrate + Hydralazine66.2
Placebo67.2

[back to top]

Myocardial Extracellular Volume Fraction

Myocardial extracellular volume, expressed as percent of total tissue volume, measured by MRI (T1 mapping pre and post-gadolinium administration) (NCT01516346)
Timeframe: 24 weeks

InterventionPercentage (Mean)
Isosorbide Dinitrate29.0
Isosorbide Dinitrate + Hydralazine31.3
Placebo29.5

[back to top]

Quality of Life (Kansas City Cardiomyopathy Questionnaire Score)

Quality of life, assessed with the Kansas City cardiomyopathy questionnaire (overall summary score, which ranges from 0 to 100). Higher values imply better quality of life. (NCT01516346)
Timeframe: 24 weeks

InterventionPoints on a scale (Mean)
Isosorbide Dinitrate62.1
Isosorbide Dinitrate + Hydralazine44.9
Placebo62.1

[back to top]

Wave Reflection Magnitude

The dimensionless ratio of backward (reflected) to forward wave amplitude. Higher values imply more wave reflection. (NCT01516346)
Timeframe: 24 weeks

Interventiondimensionless ratio (Mean)
Isosorbide Dinitrate0.38
Isosorbide Dinitrate + Hydralazine0.44
Placebo0.37

[back to top]

Arbitrary Accelerometry Units (AAU) (Phase I)

To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 5-6 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo9370
Placebo Crossover to Isosorbide Mononitrate9538

[back to top]

Arbitrary Accelerometry Units (AAU) (Phase II)

To evaluate whether isosorbide mononitrate increases daily activity as assessed by 14-day averaged arbitrary accelerometry units in comparison to placebo. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 11-12 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo8824
Placebo Crossover to Isosorbide Mononitrate8900

[back to top]

Borg Score During 6 Minute Walk Test (Phase II)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. The Borg Scale consists of scale range of 0 to 10 (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). Lower values are considered to be better than higher values. (NCT02053493)
Timeframe: Week 13

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo3.8
Placebo Crossover to Isosorbide Mononitrate3.8

[back to top]

Improvement in Daily Activity - Area Under the Curve (Phase I)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Area under the curve (AUC) of arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. Area under the curve is defined as ((7*average acceleromtery units/day during 30 mg) + (7*average acceleromtery units/day during 60 mg) + (14*average acceleromtery units/day during 120 mg))/28 (NCT02053493)
Timeframe: 3-6 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo9621.4
Placebo Crossover to Isosorbide Mononitrate9714.0

[back to top]

Improvement in Daily Activity - Area Under the Curve (Phase II)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Area under the curve (AUC) of arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. Area under the curve is defined as ((7*average acceleromtery units/day during 30 mg) + (7*average acceleromtery units/day during 60 mg) + (14*average acceleromtery units/day during 120 mg))/28 (NCT02053493)
Timeframe: 9-12 weeks

Interventionaccelerometry units (Mean)
Isosorbide Mononitrate Crossover to Placebo9146.5
Placebo Crossover to Isosorbide Mononitrate9325.9

[back to top]

Improvement in Daily Activity - Hours Active Per Day (Phase I)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Hours active per day during maximal dose of study drug (NCT02053493)
Timeframe: 5-6 weeks

InterventionHours/day (Mean)
Isosorbide Mononitrate Crossover to Placebo9.4
Placebo Crossover to Isosorbide Mononitrate9.1

[back to top]

Improvement in Daily Activity - Hours Active Per Day (Phase II)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Hours active per day during maximal dose of study drug (NCT02053493)
Timeframe: 11-12 weeks

InterventionHours/day (Mean)
Isosorbide Mononitrate Crossover to Placebo9.4
Placebo Crossover to Isosorbide Mononitrate8.8

[back to top]

Improvement in Daily Activity - Slope of Daily Average (Phase I)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Slope of daily averaged arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 3-6 weeks

Interventionaccelerometry units/day (Mean)
Isosorbide Mononitrate Crossover to Placebo-3.4
Placebo Crossover to Isosorbide Mononitrate-1.3

[back to top]

Improvement in Daily Activity - Slope of Daily Average (Phase II)

To evaluate whether isosorbide mononitrate in comparison to placebo improves daily activity as measured by Slope of daily averaged arbitrary accelerometry units during study drug administration. An arbitrary accelerometer unit is calculated within the accelerometer device that is worn by the patient and represents level of activity based on patient movement. Higher values indicate more movement. 0 indicates no movement. (NCT02053493)
Timeframe: 9-12 weeks

Interventionaccelerometry units/day (Mean)
Isosorbide Mononitrate Crossover to Placebo2.6
Placebo Crossover to Isosorbide Mononitrate-3.9

[back to top]

Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase I)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life). (NCT02053493)
Timeframe: Week 7

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo57.3
Placebo Crossover to Isosorbide Mononitrate64.2

[back to top]

Kansas City Cardiomyopathy Questionnaire Overall Summary Score (Phase II)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. • The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a disease-specific patient-reported outcomes measure for patients with heart failure. It consists of 23 items, is comprised of 7 clinically relevant scales (Symptom Frequency, Symptom Burden, Symptom Stability, Physical Limitation, Social Limitation, Quality of Life, and Self-Efficacy), and yields 3 summary scores (Clinical Summary, Total Symptom, and Overall Summary Scores). Scale and summary scores range between 0 and 100, with higher scores indicating better health status (eg, better functioning, fewer symptoms, better quality of life).Higher values of the overall KCCQ score are considered to be better than lower values. (NCT02053493)
Timeframe: Week 13

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo59.1
Placebo Crossover to Isosorbide Mononitrate61.6

[back to top]

N-terminal Pro-B-type Natriuretic Peptide Level (Phase I)

To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo (NCT02053493)
Timeframe: Week 7

Interventionpg/mL (Mean)
Isosorbide Mononitrate Crossover to Placebo513.0
Placebo Crossover to Isosorbide Mononitrate542.4

[back to top]

N-terminal Pro-B-type Natriuretic Peptide Level (Phase II)

To evaluate whether isosorbide mononitrate improves natriuretic peptide levels in comparison to placebo (NCT02053493)
Timeframe: Week 13

Interventionpg/mL (Mean)
Isosorbide Mononitrate Crossover to Placebo466.1
Placebo Crossover to Isosorbide Mononitrate573.3

[back to top]

Six Minute Walk Distance (Phase I)

To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity by 6 minute walk distance in comparison to placebo. (NCT02053493)
Timeframe: Week 7

Interventionmeters (Mean)
Isosorbide Mononitrate Crossover to Placebo307.8
Placebo Crossover to Isosorbide Mononitrate327.1

[back to top]

Six Minute Walk Distance (Phase II)

To evaluate whether isosorbide mononitrate (ISMN) improves functional capacity by 6 minute walk distance in comparison to placebo. (NCT02053493)
Timeframe: Week 13

Interventionmeters (Mean)
Isosorbide Mononitrate Crossover to Placebo321.3
Placebo Crossover to Isosorbide Mononitrate329.7

[back to top]

Patient Preference for Isosorbide Mononitrate Treatment at the End of Study.

Self reported participant preference for study period 1 vs. study period 2. (NCT02053493)
Timeframe: Week 13

,
Interventionparticipants (Number)
Phase1Phase2No Preference
Isosorbide Mononitrate Crossover to Placebo141816
Placebo Crossover to Isosorbide Mononitrate142419

[back to top]

Borg Score During 6 Minute Walk Test (Phase I)

To evaluate whether isosorbide mononitrate improves quality of life in comparison to placebo. The Borg Scale consists of scale range of 0 to 10 (where 0 indicates no breathlessness at all and 10 indicates maximum breathlessness). Lower values are considered to be better than higher values. (NCT02053493)
Timeframe: Week 7

Interventionunits on a scale (Mean)
Isosorbide Mononitrate Crossover to Placebo4.1
Placebo Crossover to Isosorbide Mononitrate4.0

[back to top]

Biopsies

Histological changes in ulcers (NCT02789033)
Timeframe: 75 days

,,,
InterventionUI/dL (Mean)
α-smooth muscle actinVon Willebrand Factorvascular endothelial growth factor-Adesmin
Active Comparator: Chitosan2.462.382.232.3
Active Comparator: Isosorbide Dinitrate Spray2.642.282.62.5
Combination: IDS and Chitosan2.562.312.432.6
Placebo Comparator: Placebo2.072.152.072.3

[back to top]

Coronary Artery Bypass [Coronary Revascularization]

Number of Participants with revascularization coronary procedures (coronary artery bypass grafting) (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Safety and Tolerability 3

Kidney injury: mean values of the microalbuminuria (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmg/mol (Mean)
Baseline1 year
Pioglitazone + Standard Care31.4431.10
Standard Care41.137.70

[back to top]

Safety and Tolerability 1

Liver injury: mean values of ALT (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionunits per liter (U/L) (Mean)
BaselineMean values of ALT in 6 monthsMean values of ALT in 1 year
Pioglitazone + Standard Care23.427.419.9
Standard Care26.926.123.9

[back to top]

Safety and Tolerability 4

Kidneys injury: mean values of creatinine (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionμmol/l (Mean)
Mean values of creatinine in men baselineMean values of creatinine in men in 1 yearMean values of creatinine in women baselineMean values of creatinine in women in 1 year
Pioglitazone + Standard Care105.685.066.872.5
Standard Care102.382.088.277.5

[back to top]

Thickness of the Intima-media Complex

Mean thickness of carotid intima-media complex (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventioncm (Mean)
Mean thickness of the right carotid intima-media baselineMean thickness of the right carotid intima-media in 6 monthMean thickness of the right carotid intima-media in 1 yearMean thickness of the left carotid intima-media baselineMean thickness of the left carotid intima-media in 6 monthMean thickness of the left carotid intima-media in 1 year
Pioglitazone + Standard Care1.081.051.011.11.061.02
Standard Care0.980.971.011.01.000.97

[back to top]

Systemic Inflammation Level

Number of Participants with C-reactive protein level above 3 mg/L (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
BaselineIn 1 year
Pioglitazone + Standard Care1012
Standard Care713

[back to top]

Percutaneous Coronary Intervention [Coronary Revascularization]

Number of Participants with incidence of percutaneous coronary intervention. (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Cardiovascular Hospitalization

Number of Participants with acute coronary syndrome (ACS) or unstable angina (UA) (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Carotic Atherosclerotic Lesions

Number of Participants with presence of atherosclerotic plaque of the intima media of common carotid artery greater than 1.4 mm (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Сardiovascular Death

Number of Participants with cardiovascular death (NCT03011775)
Timeframe: Baseline and 1 year

,
InterventionParticipants (Count of Participants)
Baseline1 year
Pioglitazone + Standard Care00
Standard Care00

[back to top]

Diameter of Stenosis [Carotic Atherosclerotic Lesions]

Mean diameters of the stenosis of the right and left common carotid arteries (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmm (Mean)
Mean diameter of the stenosis of the right common carotid artery baselineMean diameter of the stenosis of the right common carotid artery in 1 yearMean diameter of the stenosis of the left common carotid artery baselineMean diameter of the stenosis of the left common carotid artery in 1 year
Pioglitazone + Standard Care9.85.011.64.1
Standard Care8.74.810.15.6

[back to top]

Level of Insulin Resistance 1

Oral glucose tolerance test: number of Participants with impaired glucose tolerance (NCT03011775)
Timeframe: 6 months

,
InterventionParticipants (Count of Participants)
Number of Participants with glucose level in the range of 7.8 to 11 mmol/L baselineNumber of Participants with glucose level in the range of 7.8 to 11 mmol/L in 6 monthNumber of Participants with glucose level above 11 mmol/L baselineNumber of Participants with glucose level above 11 mmol/L in 6 month
Pioglitazone + Standard Care713105
Standard Care141643

[back to top]

Level of Insulin Resistance 2

Mean levels of blood glucose (NCT03011775)
Timeframe: Baseline and 6 months

,
Interventionmmol/L (Mean)
BaselineIn 6 month
Pioglitazone + Standard Care6.05.97
Standard Care5.95.60

[back to top]

Lipid Metabolism 1

Mean levels of total serum cholesterol (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionmmol / l (Mean)
Mean values of the total cholesterol level baselineMean values of the total cholesterol level in 6 monthMean values of the total cholesterol level in 1 year
Pioglitazone + Standard Care5.274.54.5
Standard Care5.284.34.3

[back to top]

Lipid Metabolism 2

Mean values of the triglyceride levels (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Intervention1 mmol/L (Mean)
Mean values of triglyceride baselineMean values of triglyceride in 6 monthMean values of triglyceride in 1 year
Pioglitazone + Standard Care0.690.720.9
Standard Care0.610.730.7

[back to top]

Lipid Metabolism 3

Lipoproteine fractions:mean values of high-density lipoproteins and low density lipoproteins (NCT03011775)
Timeframe: Baseline and 1 year

,
Interventionmmol/L (Mean)
Mean values of high-density lipoproteins in men baselineMean values of high-density lipoproteins in men in 1 yearMean values of high-density lipoproteins in women baselineMean values of high-density lipoproteins in women in 1 yearMean values of low density lipoproteins in men baselineMean values of low density lipoproteins in men in 1 yearMean values of low density lipoproteins in women baselineMean values of low density lipoproteins in women in 1 year
Pioglitazone + Standard Care0.81.10.91.23.92.94.53.3
Standard Care0.91.01.11.04.43.03.52.7

[back to top]

Safety and Tolerability 2

Liver injury: mean levels of total bilirubin (NCT03011775)
Timeframe: Baseline, 6 month and 1 year

,
Interventionμmol/l (Mean)
BaselineMean values of total bilirubin in 6 monthMean values of total bilirubin in 1 year
Pioglitazone + Standard Care12.312.415.7
Standard Care10.812.715.0

[back to top]

Cesarean Delivery Rate

Rate of cesarean section for those enrolled in study (NCT03171480)
Timeframe: 7 days

InterventionParticipants (Count of Participants)
Monoket Pill29
Placebo22

[back to top]

Placental Abruption, Use of IV Antihypertensive Drug, Maternal Hypotension, Uterine Hyperstimulation and Meconium Stained Fluid

placenta abruption at time of delivery, administration of IV antihypertensive medication for BP >160/110, maternal hypotensive defined as <90/50, Uterine hyperstimulation defined as >3 contractions in 10 minutes and meconium stained amniotic fluid anytime during labor induction/augmentation (NCT03171480)
Timeframe: during the induction of labor till delivery for all outcomes

,
InterventionParticipants (Count of Participants)
AbruptionAnti-hypertensiveshypotensionuterine hyperstimulationMSAF
Monoket Pill029930
Placebo Pill032810

[back to top]

Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 2

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate1
Placebo0

[back to top]

Number of Participants With a Reduction in UPC of > 500 mg/Day From That Measured Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 3

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo1

[back to top]

Number of Participants With a Reduction in Urine Protein Creatinine Ratio (UPC) of > 500 mg/Day From That Measured Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 1

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate1
Placebo0

[back to top]

Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 1

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate0
Placebo0

[back to top]

Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 2

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate0
Placebo0

[back to top]

Number of Participants With Improvement in Estimated Glomerular Filtration Rate (eGFR) ≥25% From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Month 3

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate1
Placebo0

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 1

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate0
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 10

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate2
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 11

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 12

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 2

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate2
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 3

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 4

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate4
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 5

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate2
Placebo1

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 6

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 7

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 8

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Number of Participants With Reduction in Systolic Blood Pressure (SBP) of ≥ 10 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 5 mm Hg From Before Enrollment

(NCT04051957)
Timeframe: Baseline, Week 9

InterventionParticipants (Count of Participants)
Isosorbide Mononitrate3
Placebo2

[back to top]

Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Heart Rate Response

Obtain estimates of the effect the study medication has on maximal exercise test heart rate response in Fontan patients by study participants performing a maximal ramp exercise test on a stationary bike. (NCT04297241)
Timeframe: Baseline and 6 weeks

Interventionbpm (Median)
Isosorbide Dinitrate - Baseline156.6
Isosorbide Dinitrate - Post-therapy164.7

[back to top]

Effect of Isosorbide Dinitrate on Maximal Exercise Capacity Respiratory Rate Response

Obtain estimates of the effect the study medication has on maximal exercise test respiratory rate response in Fontan patients by study participants performing a maximal ramp exercise test on a stationary bike. (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionRespiratory Exchange Ratio (Median)
Isosorbide Dinitrate - Baseline1.17
Isosorbide Dinitrate - Post-therapy1.19

[back to top]

Effect of Isosorbide Dinitrate on Maximal Exercise Capacity VO2 Max

Obtain estimates of the effect the study medication has on maximal exercise test VO2 max performance in Fontan patients by study participants performing a maximal ramp exercise test on a stationary bike. (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionmL/min (Median)
Isosorbide Dinitrate - Baseline1086.7
Isosorbide Dinitrate - Post-therapy1151.3

[back to top]

Effect of Isosorbide Dinitrate on Liver Stiffness Levels

Determine effectiveness of study medication on hemodynamic profile by completing baseline and post-study medication liver ultrasound measuring liver stiffness levels by sheer wave speed (m/s). (NCT04297241)
Timeframe: Baseline and 6 weeks

Interventionm/s (Median)
Isosorbide Dinitrate - Baseline2.3
Isosorbide Dinitrate - Post-therapy2.1

[back to top]

Effect of Isosorbide Dinitrate on Central Venous Pressure

Determine effectiveness of study medication on hemodynamic profile by completing baseline and post-study medication maximal exercise tests to measure central venous pressure via IV catheter insertion (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionmmHg (Median)
Isosorbide Dinitrate - Baseline22.5
Isosorbide Dinitrate - Post-therapy20.6

[back to top]

Number of Participants Who Experience an Adverse Reaction to the Study Medication During the Study Enrollment Period.

Potential adverse side effects of study medication (isosorbide dinitrate) will be monitored throughout study period. Study medication will be titrated to a maximal dose of 30mg dependent on the patient tolerance. Patient tolerance is defined by frequency of known risk factors to the study medication (headaches, hypotension, and syncope). (NCT04297241)
Timeframe: Baseline and 6 weeks

InterventionParticipants (Count of Participants)
Isosorbide Dinitrate16

[back to top]